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 2 
Abstract 27 
Disruption of mitochondrial function selectively targets tumour cells that are dependent on 28 
oxidative phosphorylation.  However, due to their high energy demands, cardiac cells are 29 
disproportionately targeted by mitochondrial toxins resulting in a loss of cardiac function. An 30 
analysis of the effects of mubritinib on cardiac cells showed that this drug did not inhibit 31 
HER2 as reported, but directly inhibits mitochondrial respiratory complex I, reducing 32 
cardiac-cell beat rate, with prolonged exposure resulting in cell death. We used a library of 33 
chemical variants of mubritinib and showed that modifying the 1H-1,2,3-triazole altered 34 
complex I inhibition, identifying the heterocyclic 1,3-nitrogen motif as the toxicophore. The 35 
same toxicophore is present in a second anti-cancer therapeutic carboxyamidotriazole (CAI) 36 
and we demonstrate that CAI also functions through complex I inhibition, mediated by the 37 
toxicophore. Complex I inhibition is directly linked to anti-cancer cell activity, with 38 
toxicophore modification ablating the desired effects of these compounds on cancer cell 39 
proliferation and apoptosis. 40 
 41 
42 
 3 
Introduction 43 
 44 
The pharmaceutical industry must deliver safe and effective medicines while simultaneously 45 
limiting the costs associated with drug development, and a central part of this process is de-46 
risking potential safety liabilities at an early stage 
1
.  In many cases, lack of mechanistic 47 
understanding about how compounds cause toxicity hampers predictions of adverse drug 48 
reactions (ADRs), and more information about the specific substructures of drug molecules 49 
that cause ADRs is required.  Such information can then be used to populate machine 50 
learning algorithms to generate adverse outcome pathways (AOPs) that predict likely 51 
outcomes 
2
 from off-target toxicities and that can be used in early phase drug design 
3
.   52 
 53 
It is widely accepted that disruption of mitochondrial function is a common cause of ADRs 54 
and it has been proposed that mitochondrial toxicity, which has a major role in idiosyncratic 55 
drug toxicity 
4
, is responsible for up to 50% of post-market drug withdrawals 
5,6
.  56 
Mitochondrial toxins often have a differential effect on tissue function due to organ-specific 57 
variations in the mitochondrial proteome and its function 
7
; primarily biosynthetic and 58 
metabolic in liver, and energy production in muscle 
8, 9
.   For example, cardiomyocytes, 59 
which have high energy requirements and are rich in mitochondria 
10
, are particularly 60 
sensitive to mitochondrial toxins that alter ATP production 
11
.  Mitochondria are central to 61 
many cell-wide processes so mitochondrial toxicity affects bioenergetics, metabolism, 62 
signalling and oxidative stress 
12
 in addition to impacting stemness, differentiation and 63 
apoptosis 13.  Due to these pleiotropic roles, “off-target” drug toxicity resulting in impairment 64 
of mitochondrial function can easily be misattributed to other targets and cellular processes. 65 
   66 
 4 
Given the relative paucity of mechanistic knowledge relating specific drug substructures to 67 
ADRs we carried out a detailed chemical dissection of mubritinib, which was reported to act 68 
as a tyrosine kinase (HER2) inhibitor and which has been trialled as a treatment for a range of 69 
cancers 
14, 15
.  However, mubritinib has also been shown to affect energy status 
16, 17
, and it 70 
was recently demonstrated to have an “off-target” effect on mitochondrial function through 71 
inhibition of respiratory complex I in cells derived from patients with Acute Myeloid 72 
Leukaemia (AML), leading to a new therapeutic option 
16
.   73 
 74 
Here, we show that mubritinib does not bind directly to HER2 and that its inhibitory effect on 75 
complex I negatively impacts on cardiomyocyte function, an important clinical consideration. 76 
Through the use of a focussed chemical library, we show that modifying the 1H-1,2,3-triazol-77 
1-yl moiety present in mubritinib substantially alters both the inhibition of complex I and the 78 
toxicity to cardiomyocytes; identifying a heterocyclic 1,3-nitrogen motif as being key to its 79 
complex I inhibitory action.  A search of chemical space was then undertaken for the same 80 
substructure, and led to the drug carboxyamidotriazole (CAI), which has also been trialled as 81 
an anti-cancer agent 
17,18-20
.  We show that, like mubritinib, CAI does not directly inhibit its 82 
reported target (calcium channels) and is also a potent complex I inhibitor.  Furthermore, like 83 
mubritinib, chemically altering the triazole ring moiety ablated toxicity.  In both cases we 84 
show that mitochondrial toxicity is directly linked to anti-cancer activity, as chemical 85 
manipulation of the toxicophoric heterocycle ablates the desired effects of both compounds 86 
on cancer-cell proliferation and apoptosis. Thus, we have identified a novel toxicophoric 87 
motif that is mechanistically linked to an adverse cardiac cell event.  Our data demonstrate 88 
that caution must be taken when attributing a drug mechanism of action without detailed 89 
structure activity relationship (SAR) analysis, since inhibition of mitochondrial function has 90 
such cell-wide effects. 91 
 5 
Results 92 
 93 
Mubritinib is not a direct HER2 inhibitor, but instead inhibits ATP production in h9c2 94 
cells and reduces beat rate in cardiomyocytes 95 
 96 
Previous data have reported that mubritinib inhibits phosphorylation of HER2 in breast 97 
cancer cell lines that express high levels of this receptor 
14
.  Therefore, the HER2-98 
overexpressing cell line, BT474, was treated with increasing doses of mubritinib and the 99 
effect on HER2 phosphorylation was analysed by Western blotting, with the specific HER2 100 
inhibitor lapatinib 
21
 as a positive control (Figure 1A, Figure 1-figure supplement 1A).  101 
Surprisingly, there was only a small decrease in HER2 phosphorylation in the presence of 102 
mubritinib, in contrast to lapatinib.  Furthermore, recent data have further shown that 103 
mubritinib, in common with known inhibitors of mitochondrial respiratory complex I 
22
, 104 
alters the phosphorylation status of proteins that sense changes in energy status and stimulate 105 
cellular proliferation, such as mTOR 
23
.   In agreement with these data, we show that 106 
treatment of cells with mubritinib (Figure 1B) alters the phosphorylation status of proteins 107 
downstream of the energy sensor AMPK (e.g. acetyl-CoA carboxylase) and impacts on 108 
mTOR signalling (e.g. phosphorylation of RPS6, Figure 1-figure supplement 1B). Moreover, 109 
similar effects were also observed with treatment by the known mitochondrial inhibitors, 110 
rotenone and antimycin A (Figure 1B and Figure 1-figure supplement 1Ci and ii).   In 111 
contrast, lapatinib, which is a specific HER2 inhibitor, blocks signalling downstream from 112 
mTOR with minimal effect on ACC phosphorylation (Figure 1B, Figure 1-figure supplement  113 
1Ci and ii), but a large effect on RPS6 (Figure 1-figure supplement 1Ci and ii).  An inactive 114 
mubritinib analogue (compound 5, see below) was used as a negative control.  An in vitro 115 
tyrosine kinase activity assay was then carried out with increasing concentrations of 116 
 6 
mubritinib, in which recombinant human HER2 was incubated with radioactively labelled 117 
32
P-ATP.  Mubritinib did not decrease 
32
P incorporation, even at 10 M (Figure 1C and 1D), 118 
demonstrating that it does not inhibit HER2 phosphorylation. Furthermore, consistent with 119 
our data (Figure 1E), mubritinib has been reported to display no activity against almost 300 120 
other kinases screened 
24
.   121 
 122 
Because mubritinib affects signalling pathways associated with a decrease in cellular energy, 123 
and because inhibiting mitochondrial respiration could have particularly deleterious effects 124 
on tissues with high energy demand such as the heart, we tested the effect of mubritinib on 125 
ATP production in H9c2 cardiomyoblasts 
25
 and human embryonic stem cell derived 126 
cardiomyocytes (hESC-CM, GE Healthcare) using the glucose/galactose system.  In 127 
galactose-containing media cells are predominantly reliant on mitochondria for the 128 
production of cellular ATP, allowing mitochondrial liabilities that are masked in glucose to 129 
be revealed 
26,27
.   130 
 131 
Exposure of H9c2 cells to 2 M mubritinib for 2 hours in galactose-containing media led to a 132 
50% decrease in ATP levels (Figure 1F).  Furthermore, prolonged exposure depleted ATP 133 
levels to 10% of the control value (Figure 1F) and induced cell death (Figure 1G). 134 
Importantly, inhibition of ATP production in galactose (but not glucose) containing media by 135 
mubritinib and other inhibitors of oxidative phosphorylation was also observed in hESC-CMs 136 
(Figure 1H) and had a profound effect on cell beat rate (Figure 1I).   137 
 138 
 139 
 140 
 7 
Structure activity relationships (SARs) determined using a library of derivatives to identify 141 
a novel toxicophore in mubritinib 142 
 143 
It has been shown recently that mubritinib targets respiratory complex I and inhibits growth 144 
of cancer cells from patients with AML, which are highly dependent on oxidative 145 
phosphorylation for survival 
16
.  Therefore, to understand likely toxicities associated with 146 
such treatments, we investigated whether complex I is similarly affected in cardiomyocytes 147 
exposed to mubritinib (1), and used a focussed chemical library of mubritinib derivatives (2-148 
8) to identify the potential toxicophore (Figure 2A).   The mubritinib variants were 149 
synthesised with modifications in two regions of the molecule; the aryl trifluoromethyl group 150 
(compounds 2-4) and the triazole group (compounds 5-8). 151 
  152 
The oxygen consumption rates (OCR) of H9c2 and hESC-CM cells treated with mubritinib 153 
(1) were measured to determine whether the decreased ATP content in galactose containing 154 
media (Figures 1F and 1H) were due to direct inhibition and/or uncoupling of the respiratory 155 
chain 
28
.  As expected, oligomycin A, which inhibits ATP synthase, had no effect on the 156 
rotenone-sensitive OCR in the presence of the uncoupling agent FCCP (carbonyl cyanide-4-157 
(trifluoromethoxy) phenylhydrazone). However, in H9c2 or hESC-CMs cells exposed to 158 
mubritinib the rotenone-sensitive OCR decreased by ~50% (Figure 2B and Figure 2- figure 159 
supplement 1 A and B).  Taken together, these data suggest that mubritinib (1) inhibits the 160 
mitochondrial respiratory electron transport chain in cardiomyocytes. 161 
 162 
The effects of mubritinib (1) on complex I and II linked respiration were then determined in 163 
plasma-membrane permeabilised H9C2 cells.  First, cells were pre-treated with increasing 164 
doses of mubritinib (1), or the complex I inhibitor rotenone or the complex III inhibitor 165 
 8 
antimycin A.  As expected, all inhibitor treatments decreased the OCR (Figure 2C).  Cells 166 
were then treated with plasma membrane permeabiliser followed by addition of ADP. 167 
Pyruvate/malate and succinate were used to drive respiration from complex I and complex II, 168 
respectively and, in untreated cells, they both stimulated the OCR.  All three inhibitors 169 
inhibited pyruvate/malate-driven respiration but, crucially, the inhibition of only mubritinib 170 
and rotenone was alleviated by subsequent treatment with succinate (Figure 2C), suggesting 171 
that mubritinib is a complex I inhibitor.   172 
 173 
Mitochondrial membranes were then used to assess the effect of mubritinib (1) on complex I 174 
and complex II driven respiration directly.  In agreement with the data obtained from cell 175 
lines, mubritinib (1) showed a dose-dependent decrease in the rate of NADH oxidation and 176 
no effect on succinate oxidation (Figures 2D and 2E).  The NADH oxidation data were then 177 
fit to the standard dose-effect relationship and yielded an IC50 value of 19.2 nM (Figure 2D). 178 
 179 
Purified complex I was then used to confirm inhibition of complex I unambiguously, and to 180 
dissect whether mubritinib (1) inhibits it at its NADH or ubiquinone binding site.  NADH 181 
oxidation was coupled to reduction of either the ubiquinone-10 analogue decyclubiquinone 182 
(dQ) or to reduction of an artificial electron acceptor (APAD
+
 or ferricyanide, FeCN) that 183 
reoxidises the flavin in the NADH binding site directly 
29
 
30
, without the involvement of 184 
ubiquinone (Figure 2E) 
29
. While APAD
+
 and FeCN reduction were unaffected at 500 nM 185 
mubritinib (1), the rate of ubiquinone reduction was essentially abolished (Figure 2E).  These 186 
data confirm that mubritinib inhibits complex I directly by inhibiting ubiquinone reduction, 187 
most likely by binding in the ubiquinone-binding site. 188 
 189 
 9 
The variants of mubritinib were then tested for their ability to inhibit complex I in 190 
mitochondrial membranes (Figure 2F and Figure 2-figure supplement 2 Ai-viii).  191 
Compounds 2-4 (Figure 2A), which have the same N
1
-linked triazole moiety as mubritinib 192 
but contain either no substituent (2) or a mild (3) or strong (4) electron donating group in the 193 
para-position of the phenyl ring, retain the ability to inhibit complex I, similarly to mubritinib 194 
(Figure 2F).  In contrast, compound 6, which has the 1,2,3-triazol-1-yl moiety substituted for 195 
an isomeric 1,2,3-triazol-2-yl group, is a much weaker inhibitor (Figure 2F).  Complete 196 
removal of the triazole group in 5 and modification of the triazole to an N-linked pyrrole in 8, 197 
also resulted in compounds that no longer inhibited NADH oxidation (Figure 2F).  Most 198 
interestingly, modification of the triazole to the N-linked imidazole 7 retained the inhibitory 199 
activity.  These data provide strong evidence that a 1,3-amidine-like motif, housed within the 200 
1H-1,2,3-triazol-1-yl substituent, is required for complex I inhibition.  The same pattern of 201 
inhibition was observed for ATP production in cells grown in media containing galactose 202 
(Figure 2G). Therefore, inhibition of ATP production by mubritinib results from the 203 
inhibition of complex I, and depends strongly upon its 1,2,3-triazol-1-yl moiety and the 204 
embedded toxicophore.   205 
 206 
The 1,2,3-triazol-1-yl toxicophore in carboxyamidotriazole (CAI) inhibits ATP production, 207 
mitochondrial function and cell proliferation 208 
 209 
Based on the 1H-1,2,3-triazol-1-yl moiety being critical for the function of mubritinib we 210 
initially searched for other compounds that contain a 1,2,3-triazol-1-yl or similar moiety that 211 
might display analogous toxicity profiles.  A structural similarity search carried out on the 212 
ChEMBL database revealed a range of terminal 1,2,3-triazole-containing drugs as putative 213 
complex I inhibitors (Supplementary File 1) including carboxyamidotriazole (9, Figure 3A), 214 
 10 
which has been trialled widely as an anticancer agent in single and combination therapies to 215 
treat glioblastoma, ovarian cancer and non-small cell lung cancer 
19, 20
.   Data from a number 216 
of studies have suggested that the anti-proliferative and anti-metastatic properties of CAI (9) 217 
are mediated through the inhibition of non-voltage gated Ca
2+
 channels in non-excitable cells 218 
31
, which in turn modulates downstream phosphorylation events 
32
, however this has not been 219 
demonstrated directly.   Calcium binding assays performed here show clearly that there is no 220 
significant binding of CAI (9) to non-voltage gated Ca
2+
 channels (Supplementary File 2).  It 221 
has also been shown that CAI (9) affects mitochondrial calcium import and local calcium 222 
clearance, which is essential for the maintenance of capacitative calcium entry 
33
 and it was 223 
proposed that this then inhibited oxidative phosphorylation 
34
.  These data suggest that the 224 
toxicophore, in the context of CAI (9), might act in a similar way to mubritinib, and that the 225 
effects on mitochondrial calcium release could be the secondary effects of complex I 226 
inhibition.  To explore the effect of the heterocycle in CAI (9) on mitochondrial function we 227 
generated three variants.  Two compounds, which we predicted by analogy with our 228 
mubritinib variants that would be inactive, contained isomeric pyrazoles (10 and 11).   One 229 
further compound was synthesised where the triazole ring in CAI was replaced with an 230 
imidazole ring (12), which we predicted would retain mitochondrial toxicity (Figure 3A).  231 
The set of compounds was then tested in H9c2 cardiomyoblasts for their effects on oxygen 232 
consumption rates and ATP production (Figure 3B and 3C).  CAI (9) and compound 12 233 
inhibited ATP production in galactose containing media much more strongly than compounds 234 
10 and 11 (Figure 3B). Similarly, CAI (9) and compound 12 decreased oxygen consumption 235 
rates much more effectively than compounds 10 and 11 (Figure 3C and Figure 3-figure 236 
supplement 1). 237 
 238 
 11 
Given that CAI has been trialled as an anti-cancer therapeutic against lung cancer 
20
, CAI (9) 239 
and compounds 10 and 11 were tested in the lung cancer derived cell line, A459, to determine 240 
whether the effects on mitochondrial function observed in the Hc92C cardiomyoblasts were 241 
replicated.  The data show that CAI (9) inhibits ATP production in A549 cells grown in 242 
galactose, whereas 10 and 11 have minimal effect (Figure 3D) with no difference observed, 243 
as expected, in glucose containing media (Figure 3-figure supplement 1C).  Moreover, the 244 
basal and maximal OCR of cells treated with CAI (9) were significantly reduced, with a 245 
much smaller decrease observed with compounds 10 and 11 (Figure 3E and Figure 3-figure 246 
supplement 1).   247 
To confirm that CAI inhibited complex I, A549 cells were treated with PMP followed by 248 
addition of ADP, pyruvate and malate (Figure 3F).  In untreated cells, or cells treated with 10 249 
and 11, there was a large increase in oxygen consumption as expected, however, oxygen 250 
consumption was inhibited in cells treated with CAI (9), antimycin A or piericidin. Following 251 
addition of succinate and ADP there was an increase OCR in CAI (9) and piericidin-treated 252 
cells (but not in cells treated with antimycin A), strongly suggesting that CAI (9) is a 253 
complex I inhibitor. Importantly, given that compounds 10 and 11 only have a small effect, in 254 
this chemical context the triazolyl toxicophore contributes in a similar manner to mubritinib.  255 
To confirm these data, mitochondrial membranes were used to assess the impact of each 256 
compound on complex I-driven respiration. As expected, both CAI (9) and 12 inhibited 257 
complex I-driven respiration whereas compounds 10 and 11 have essentially no effect (Figure 258 
3G), as reflected by the measured IC50 values for each compound (Figure 3-figure 259 
supplement 2). Similar to mubritinib, inhibition of complex I with CAI also effects signalling 260 
pathways downstream of the energy sensor AMPK, such as increased ACC phosphorylation 261 
and inhibition of mTOR signalling reducing RPS6 phosphorylation (Figure 3-figure 262 
 12 
supplement 3). Importantly these pathways are unaffected by the non-specific calcium 263 
channel inhibitor bebridil hydrochloride or the inactive CAI variant compound 11.  264 
 265 
Inhibition of cell proliferation and cell death by CAI and mubritinib via complex I 266 
inhibition is dependent on the toxicophore 267 
 268 
To confirm that the toxicophore we have identified is directly linked to the reported anti-269 
proliferative/cancer chemotherapeutic properties of mubritinib (1) and CAI (9), the degree of 270 
cell death following treatment with these compounds was measured in a range of cancer 271 
derived cell lines.  The cells lines used were representative of AML (HL60), glioblastoma 272 
(M059K), lung (A549), osteosarcoma (U-20S), in addition to HeLa cells since these cancers 273 
display varying degrees of dependence on glycolysis versus oxidative phosphorylation for 274 
energy production and to provide key metabolites required for tumour cell survival 
35, 36
.  275 
Cells were grown in galactose or glucose containing media in the presence of mubritinib (1), 276 
CAI (9), or a corresponding inactive variant, 5 or 11 respectively, and the degree of cell death 277 
was measured using DRAQ7™ staining and Annexin-V-FITC labelling (Figure 4 and Figure 278 
4-figure supplement 1).  The data show that treatment of the AML derived cell line with 279 
either CAI (9) or mubritinib (1) caused cell death in both glucose and galactose, while the 280 
analogue compounds which lacked the heterocyclic 1,3-nitrogen motif had no effect (Figure 281 
4A and 4B, Figure 4-figure supplement 1).  The other cell lines used showed no cell death in 282 
the presence of glucose (Figure 4D, 4F and Figure 4-figure supplement 1D, F and G), 283 
however again there was a correlation between the presence of the toxicophore and cell death 284 
in galactose (Figure 4C, 4E and Figure 4-figure supplement 1C, E and H).   To explore 285 
whether the toxicophore had similar effects on cell growth, BT474 (Figure 4G) and A549 286 
(Figure 4H) cells were grown in glucose and proliferation measured using xCELLigence 287 
 13 
RTCA DP instrument.  Again, the data show a direct correlation between the presence of the 288 
1,2,3-triazole and cell growth inhibition as both mubritinib (1) and CAI (9) slowed cell 289 
growth, whereas the analogues, which lacked the heterocyclic 1,3-nitrogen motif, had 290 
reduced or no effect.   291 
 292 
Taken together these data establish that the presence of the triazole and its embedded 293 
heterocyclic 1,3-nitrogen toxicophore is essential for the parent drug effects on tumour cell 294 
growth of otherwise chemically distinct mubritinib and CAI. 295 
 296 
Discussion 297 
Our data show the value of using SARs to probe the molecular signatures that potentially 298 
trigger toxicity pathways and, through the identification of a novel toxicophore, have 299 
implications for drug development programmes (Figure 5).  The toxicophore in the context of 300 
mubritinib and CAI is the embedded 1,3-nitrogen motif of the 1H-1,2,3-triazol-1-yl 301 
heterocycle and we have shown that this nitrogen atom disposition appears critical for both 302 
mitochondrial toxicities (Figures 1-4).  In a preliminary screen of compounds that inhibited 303 
complex I, we identified two antifungal agents, ketoconazole and terconazole, which also 304 
contained the heterocyclic 1,3-nitrogen motif embedded within a 1H-1,2,4-triazol-1-yl or 1H-305 
imidazol-1-yl substituent respectively (Supplementary File 3).  Interestingly, we also found 306 
that rufinamide (Supplementary File 1), which contains a chemically similar core scaffold to 307 
CAI, displayed no complex I inhibitory activity 
37
.  However, there are key structural 308 
differences between these two drugs and in particular, rufinamide lacks an anilino nitrogen in 309 
the 5-position of the 1,2,3-triazole, the para-chlorobenzoyl moiety and there is a chloro to 310 
fluoro switch with regards the halogen substituents on the N-benzyl group (alongside the 311 
switch in position from 3,5 to 2,6).  These observations are therefore coupled with a 312 
 14 
difference in the logP of rufinamide (1.3) when compared to CAI (3.1) which indicates a 313 
significant decrease in its overall lipophilicity and may therefore reflect a compromised 314 
pharmacokinetic-driven target engagement . Which of these differences drive the observed 315 
loss in complex I inhibition by rufinamide is a focus of ongoing work. 316 
It is of serious concern that while both mubritinib and CAI are trialled as part of anti-cancer 317 
therapies
16
, neither directly bind their reported targets, HER2 and Ca
2+
 channels respectively 318 
(Figure 1 and Supplementary File 2).   Mitochondria play a central role in cell-wide processes 319 
in addition to bioenergetics and metabolism by providing a signalling hub that controls 320 
stemness, differentiation and apoptosis 13, therefore disruption of mitochondrial function can 321 
easily be misattributed to other targets, such as receptors involved in cell signalling.  Cardiac 322 
cells are especially sensitive to mitochondrial toxicants that alter ATP production and our 323 
data suggest that both mubritinib and CAI have the potential to affect these cell types in 324 
situations when glucose is limiting (Figures 1, 2 and 4).  It would therefore be important to 325 
monitor patients treated with such agents for changes in cardiac function during future 326 
clinical trials of CAI or mubritinib.  327 
In terms of cancer treatment, mubritinib has been used to chemo-sensitise tumour cells to 328 
other cytotoxic agents.  For example, in combination with AC220 (quizartinb), mubritinib 329 
reduces the viability of ovarian derived cell lines 
15
.  However, sole inhibition of complex I is 330 
also a viable treatment option for some cancer types.  Thus while drugs that target the 331 
coordinated upregulation of glycolysis that is often associated with tumorigenesis are being 332 
developed, several studies have shown that many cancer cell subpopulations are particularly 333 
dependent upon OXPHOS for bioenergetic and biosynthetic processes 
38-40
.  Compounds that 334 
target the mitochondria, either complex I including mubritinib 
16
 and IACS-010759
35
, or the 335 
ATP synthase such as Giboxin 
36
, have been shown to have efficacy in glycolysis–deficient 336 
tumour cells derived from patients with AML and glioblastoma
16, 32, 36
.  Interestingly, IACS-337 
 15 
010759
32
 contains a 1H-1,2,4-triazole suggesting a similar mode of action of this drug since 338 
this heterocycle also possesses the amidine-like nitrogen substitution pattern.   339 
Since the efficacy of both mubritinib and CAI (Figure 4) is dependent upon an amidine-like 340 
nitrogen substructure our data suggest that new drug development programmes using this 341 
substructure within the correct chemical context could be employed to devise therapies for 342 
glycolysis deficient tumours, providing that cardiac liabilities are assessed and evaluated.  343 
Therefore, a more detailed examination of potential molecular recognition of these and other 344 
substructures by complex I is ongoing within our laboratories, coupled with consideration of 345 
target access from a pharmacokinetic perspective to allow repurposing of a number of drugs 346 
for their anti-cancer properties.   347 
348 
 16 
Material and Methods 349 
 350 
 351 
Cell Culture 352 
All cell lines were obtained from ATCC, except hESC-cardiomyocytes which were obtained 353 
from GE healthcare (Cytiva
TM 
Plus, GE Healthcare). Glucose containing media consists of 354 
glucose-containing DMEM (Life Technologies, Gibco® 41966) supplemented with 10% 355 
FBS. Galactose containing media consists of glucose-free DMEM (Life Technologies, 356 
Gibco®) supplemented with 10 mM galactose, 200 mM L-glutamine, 100 mM sodium 357 
pyruvate and 10% FBS.  Prior to treatments, cells were grown in their respective media 358 
overnight. hESC-cardiomyocytes were cultured in RPMI-1640 media supplemented with 359 
either glucose (11 mM) or galactose (10 mM).  All cell lines were routinely tested to ensure 360 
that they were mycoplasma free. 361 
 362 
Western blot analyses 363 
Whole cell lysates were prepared in lysis buffer (50 mM Tris pH 7.5, 150 mM sodium 364 
chloride, 1% Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 1X Roche protease 365 
inhibitor cocktail and 1X Roche PhosStop phosphatase inhibitor cocktail). Protein amount 366 
was quantified using Pierce BCA protein assay kit (ThermoFisher scientific) and 25 μg 367 
protein was separated using SDS-PAGE and transfered to PVDF membranes. Primary 368 
antibodies used: phospho-HER2 (Y1221/1222) (CST, #2243), HER2 (CST, #2165), phospho-369 
ACC (S-79) (CST, #3661), ACC (CST, #3676), phospho-RPS6 (S240/244) (CST, #2215), 370 
RPS6 (CST, #2217), β-tubulin (CST, #2146). Secondary antibodies used: IR-dye labelled α-371 
rabbit (CST, #5366S). Fluorescent signal was detected using LI-COR Odyssey imaging 372 
system (LI-COR biosciences) and images analysed with LI-COR image studio software 373 
(package version 5.2.5).  374 
 375 
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Measurement of ATP content 376 
H9c2 rat cardiomyoblast cells and hESC-cardiomyocytes were seeded in 96 well plates at a 377 
density of 7 x 10
3
 and 3.6 x 10
5
 cells per well respectively, whereas A549 cells were seeded 378 
at a density of 1 x 10
4
 cells per well.  ATP concentrations were measured using the Promega 379 
Cell Titer Glo assay according to manufacturer’s protocol.  380 
 381 
Measurement of bioenergetics in live cells 382 
An Agilent XF Seahorse Analyzer was used to measure respiration and glycolysis in intact 383 
cells in real time. Cells were seeded in Seahorse Biosciences XF24 plates. H9c2, hESC-CM 384 
(Cytiva
TM 
Plus, GE Healthcare) and were seeded at 9 x 10
4
, and 6 x 10
4
 cells per well (coated 385 
with 25 μl fibronectin prior to seeding). Prior to the assay, media was replaced with DMEM, 386 
containing either glucose or galactose. Drugs were dissolved in DMSO and injected from pre-387 
loaded ports pneumatically. 388 
 389 
Measurement of mitochondrial respiration in permeabilised cells 390 
Cholesterol-dependent permeabilser XF Plasma Membrane Permeabiliser (PMP) (Seahorse 391 
Biosciences), was used as described
41
. Mitochondrial assay buffer or mannitol and sucrose 392 
buffer (MAS, pH 7.2) (220 mM mannitol, 70 mM sucrose, 10 mM KH2PO4, 5 mM MgCl2, 2 393 
mM HEPES, 1 mM EGTA, 4 mg/ml BSA, was used. Cells were seeded at 5 x 10
4
 per well in 394 
XF Cell Culture plates in standard culture medium. Cells were washed once with MAS 395 
before addition of pre-warmed MAS at a final volume of 675 μl. Pyruvate (5 mM), malate 396 
(2.5 mM) and ADP (1 mM) were added for measurement of complex I-driven respiration and 397 
succinate (10 mM) and ADP (1 mM) for complex II-driven respiration. 398 
 399 
Preparation of proteins and mitochondrial membranes 400 
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Mitochondrial membranes and complex I were prepared from bovine (Bos taurus) heart 401 
mitochondria as described previously 
42,43
. 402 
 403 
NADH oxidation assays by mitochondrial membranes and complex I 404 
Assays were performed in 10 mM Tris SO4 (pH 7.5), 250 mM sucrose at 32 °C. For 405 
measurement of NADH:O2 oxidoreduction, 20-30 g mL
-1
 of membranes, 1 or 3 M horse 406 
heart cytochrome c, and 120 or 200  M NADH were added and the absorbance of NADH 407 
measured at 340-380 nm using linear regression, once steady-state was reached. Succinate 408 
oxidation was determined using a coupled enzymatic assay 
44
 in the presence of 5 mM 409 
succinate. NADH:decylubiquinone (dQ), NADH: 3-acetylpyridine adenine dinucleotide 410 
(APAD
+
), and NADH:ferricyanide (FeCN) oxidoreduction by complex I were measured 411 
using 0.5 g mL-1 complex I, 100 M NADH, 0.075% soy bean asolectin (Avanti Polar 412 
Lipids), 0.075% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS, 413 
Merck Chemicals Ltd,) and 100 M dQ, 500 µM APAD+ or 1 mM FeCN, respectively. 414 
 415 
Quantification of cardiac cell function in hESC-CM using multi-electrode arrays (MEA)  416 
MEA plates (Axion Biosystems, M768-KAP-48) contain 48 wells, each with 16 electrodes. 417 
hESC-CM were grown on these plates and incubated with the doses of mubritinib shown and 418 
recordings were taken over a time course up to 72 hours.  AxIS (Version 2.0.2.9) cardiac beat 419 
detector which uses an inflection search algorithm was used to detect changes in cardiac 420 
action potential. 421 
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 422 
Apoptosis and cell death analysis 423 
For analysis of cell death and apoptosis, cells were harvested and FITC-conjugated Annexin-424 
V antibody and far-red DNA stain DRAQ7™ were added to pellets resuspended in Annexin-425 
V Binding Buffer (BD Pharmingen). Samples were analysed by flow cytometry using the 426 
FITC and APC channels. 427 
 428 
Assays for ion channel binding 429 
Ion channel binding assays were carried out by Eurofins Panlabs Discovery Services Taiwan 430 
Ltd. The binding affinity of compounds to ion channels was measured using an in vitro 431 
radioligand binding assay ([
3
H] 1,4,5-IP3) in rat cerebellum, following incubation at 25 
o
C 432 
for 10 minutes. All data are displayed show a percentage binding of each compound relative 433 
to control 1,4,5-IP3. 434 
 435 
Assays for activity against HER2 436 
A radiometric kinase assay was carried out by Eurofins Ltd.  In brief, the effect of mubritinib 437 
on recombinant human HER2 activity was determined by measuring the incorporation of 438 
radioactive 
32
P-ATP using concentrations from 10 nM to 10 M. Activity values represent 439 
the percentage relative to the positive control. Mubritinib was also tested for activity against 440 
EGFR, ErbB4, Flt1 and PDGRα at a concentration of 1 M. Lapatinib was tested against 441 
HER2 as a positive control. The experiments were carried out in triplicate and the counts per 442 
minute (CPMs) were normalised to the control. 443 
 444 
Cell proliferation assays 445 
 20 
Cell proliferation assays were performed in a standard CO2 incubator using the xCELLigence 446 
RTCA DP instrument (ACEA Biosciences) according to manufacturer’s instructions. 447 
Microelectrode sensor arrays embedded on the base of the E-plate 16 (ACEA Biosciences) 448 
measure changes in impedance as cells attach and proliferate, enabling label free 449 
quantification of cell proliferation. A549 or BT474 cells were seeded on an E-plate 16 in a 450 
total volume of 150 µl media. Cells were allowed to attach to the plate and enter log phase 451 
growth (~ 20 hours) before treatment with indicated compounds of interest.  Cell proliferation 452 
was monitored for 96 hours post treatment and all treatments were performed in at least 453 
technical duplicate and biological triplicate.  454 
 455 
Chemical Synthesis 456 
For synthesis of mubritinib and CAI variants see supplementary material. 457 
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 588 
Figure 1: Mubritinib does not inhibit HER2, but inhibits ATP production and beat rate 589 
of cardiomyocytes 590 
A) Western blot analysis of the HER2-overexpressing cell line, BT474, treated with 591 
increasing doses of mubritinib. HER2 activity was assessed with antibodies against 592 
phosphorylated HER2 (Y1221/1222). Cells were treated with the clinically used HER2 593 
inhibitor, lapatinib (10 μM), as a positive control. 594 
B) Western blot analysis of the HER2-overexpressing cell line, BT474, treated with 1 μM of 595 
either mubritinib, lapatinib, compound 5 (inactive mubritinib derivative, see Figure 2A), 596 
antimycin A or rotenone for 2 hours. 597 
C) Radiometric kinase assays were carried out and the effect of mubritinib (at the 598 
concentrations shown) on recombinant human HER2 activity was determined by measuring 599 
the incorporation of radioactive 32P-ATP after 15 mins. Activity values are displayed relative 600 
to the untreated sample. 601 
D) Radiometric kinase assays were carried out using recombinant human HER2 in the 602 
presence of 1 μM mubritinib and lapatinib (DMSO control and lapatinib, n = 3, mubritinib, n 603 
= 2). Significance following lapatinib treatment was assessed using the unpaired students t-604 
test (*** p < 0.001) relative to the DMSO control. 605 
E) Radiometric kinase assays were carried out on recombinant human EGFR, ErbB4, Flt1 606 
and PDFRa in the presence of 2 μM mubritinib. Error bars represent standard deviation (n = 607 
3). 608 
F) A 24 hour time course for loss of ATP from H9c2 cells following treatment with 2 μM 609 
mubritinib in media containing either glucose or galactose as the carbon source. Error bars 610 
represent standard deviation (n = 3) and significance was assessed using ANOVA with 611 
Dunnett’s multiple comparisons test (**** p < 0.0001, *** p < 0.001, ns = not significant). 612 
G) H9c2 cells were treated with 2 μM mubritinib in media containing either glucose or 613 
galactose as the carbon source and cell viability was assessed over a 72-hour period using 614 
DRAQ7™ staining and Annexin-V-FITC labelling. Error bars represent standard deviation (n 615 
= 3) and significance at each time point was assessed using ANOVA with Tukey’s multiple 616 
comparisons test (**** p < 0.0001). 617 
H) hESC-cardiomyocytes (CytivaTM Plus, GE Healthcare) were grown in RPMI-1640 media 618 
supplemented with galactose (10 mM) or glucose (11 mM) and treated with 1 μM of 619 
mubritinib, or inhibitors of mitochondrial complex III (antimycin A), ATP synthase 620 
(oligomycin A) or complex I (rotenone). ATP levels were measured after 2 hours. Error bars 621 
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represent standard deviation (n = 4) and significance was assessed using the unpaired 622 
students t-test (**** p < 0.0001). 623 
I) hESC-cardiomyocytes (CytivaTM Plus, GE Healthcare) were grown in either galactose (10 624 
mM) or glucose (11 mM) containing media on multi-electrode array plates from which it is 625 
possible to assess beat rate. The average beat rates in glucose (i) and galactose (ii) containing 626 
media of 52.2 and 30.7 BPM respectively, were set to 100%. Cells were treated with 627 
mubritinib (1 μM), antimycin A (1 μM) or rotenone (1 μM). Error bars represent standard 628 
deviation (n = 3) and significance was assessed using the unpaired students t-test (* p <0.05, 629 
** p < 0.01, **** p < 0.0001). 630 
Figure 2: Mubritinib is an inhibitor of mitochondrial complex I 631 
A) Variants of mubritinib were synthesised with alterations to the trifluoromethylphenyl 632 
group (2, 3 and 4) or the triazole (5, 6, 7 and 8). Mubritinib (1) and mubritinib synthesised “in 633 
house” were used as positive controls.  634 
B) Rotenone-sensitive oxygen consumption rates (OCRs) of H9c2 or hESC-CM cells in 635 
glucose containing media were measured after the addition of FCCP in the presence of either 636 
1 μM mubritinib or 1 μM oligomycin A. OCR values are represented relative to untreated 637 
cells and error bars represent standard deviation (n = 3). Significance was assessed using the 638 
unpaired students t-test (*** p = < 0.001, **** p = < 0.0001, ns = not significant). 639 
C) OCR was measured in cells pre-treated with 0.5 μM, 2 μM and 10 μM mubritinib, 1 μM 640 
rotenone or 10 μM antimycin A using a Seahorse XF Analyzer. PMP was added to 641 
permeabilise the plasma membrane, followed by pyruvate, malate and ADP to drive complex 642 
I linked respiration. Then, rotenone was added to abolish complex I respiration followed by 643 
ADP and succinate to drive complex II linked respiration. Error bars represent standard 644 
deviation (n = 3). 645 
D) Mubritinib was incubated with mitochondrial membranes from bovine heart at the 646 
concentrations shown, then the rate of NADH was measured spectrophotometrically. Error 647 
bars represent standard error of the mean (n = 3). Data were fit using activity (%) = 100 / (1 + 648 
(IC50 / [inhibitor]) Hill slope and yielded an IC50 value of 19.2 nM. 649 
E) Relative rates of NADH or succinate oxidation by mitochondrial membranes or complex I 650 
isolated from bovine heart using O2, dQ, APAD+, or FeCN as the electron acceptor in the 651 
presence of 500 nM mubritinib. Error bars represent standard deviation (n = 3) and 652 
significance was assessed using ANOVA with Dunnett’s multiple comparisons test (**** p < 653 
0.0001, ns = not significant). 654 
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F) Mubritinib and the variants from (A) were incubated with mitochondrial membranes at 655 
500 nM. The rate of NADH oxidation was measured spectrophotometrically. The activity is 656 
expressed relative to the DMSO control, set to 100%. Error bars represent standard deviation 657 
(n = 3) and significance was assessed using ANOVA with Dunnett’s multiple comparisons 658 
test (**** p < 0.0001, ** p < 0.01). Activities were inter/extrapolated from measured data 659 
points for compounds 7 and 8.  660 
G) H9c2 cells were treated with mubritinib and all compound variants (10 μM) in galactose 661 
containing media for 24 hours and ATP levels were measured. Error bars represent standard 662 
deviation (n = 3) and significance was assessed using ANOVA with Dunnett’s multiple 663 
comparisons test (**** p < 0.0001, ns = not significant). 664 
Figure 3: The toxicophore present in carboxyamidotriazole inhibits mitochondrial 665 
complex I 666 
A) Chemical structure of carboxyamidotriazole (CAI) (9) and three variants whereby the core 667 
triazole ring was replaced with either a pyrazole (10 and 11) or imidazole (12). For the 668 
pyrazoles, 11 is an analogue of 9 with one of the triazole nitrogens removed, whereas 10 also 669 
removes one of the triazole nitrogen atoms whilst additionally shifting the 670 
trichlorobenzophenonemethyl moiety to the 2-position equivalent. 671 
B) H9c2 cells were treated with 3, 6 or 12 μM of CAI (9), 10, 11, 12 or the “in house” 672 
synthesised CAI in galactose containing media and after 24 hours ATP levels were measured 673 
and data shown are relative to the untreated control (n = 3). Significance was assessed using 674 
ANOVA with Dunnett’s multiple comparisons test (**** p < 0.0001, *** p < 0.001, ** p < 675 
0.01, * p < 0.05, ns = not significant). 676 
C) Basal (i) and maximum (ii) oxygen consumption rates were measured using a Seahorse 677 
XF Analyzer in H9c2 cells treated with 3 and 10 μM of either CAI (9), 10, 11, 12 or the “in 678 
house” synthesised CAI. Error bars represent standard deviation (n = 3) and significance was 679 
assessed using ANOVA with Tukey’s multiple comparisons test (**** p < 0.0001, *** p < 680 
0.001, * p < 0.05). 681 
D) A549 cells were treated with 3, 6 or 12 μM of CAI (9) or 10 and 11 in galactose 682 
containing media and after 24 hours ATP levels were measured and normalised to the 683 
untreated control. Error bars represent standard deviation (n = 3) and significance was 684 
assessed using ANOVA with Tukey’s multiple comparisons test (**** p < 0.0001). 685 
E) Basal and maximum oxygen consumption rates were measured using a Seahorse XF 686 
Analyzer in A549 cells treated with 5 μM of either CAI (9), 10, 11; or 5 μM mubritinib. Error 687 
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bars represent standard deviation (n = 3) and significance was assessed using ANOVA with 688 
Tukey’s multiple comparisons test (**** p < 0.0001). 689 
F) A549 cells were pre-treated with either 5 μM CAI (9), 10, 11, mubritinib, antimycin A or 690 
piericidin A (complex I inhibitor) and the OCR was measured over the times indicated. PMP 691 
was added to permeabilise the plasma membranes followed by addition of pyruvate, malate 692 
and ADP to drive complex I respiration and OCR determined. Finally, piericidin A was 693 
added to abolish complex I respiration followed by ADP and succinate to drive complex II 694 
respiration and OCR was again measured. Representative trace from 3 independent 695 
experiments. 696 
G) CAI (9), 10, 11, 12 and the “in house” synthesised CAI were incubated with 697 
mitochondrial membranes at 500 nM. The rate of NADH oxidation was measured 698 
spectrophotometrically. The activity is expressed relative to the DMSO control, set to 100%. 699 
Error bars represent standard deviation (n = 3) and significance was assessed using ANOVA 700 
with Tukey’s multiple comparisons test (**** p < 0.0001, ns = not significant). Activities 701 
were interpolated from measured data points for compounds 10, 11, 12 and “in house” CAI. 702 
Figure 4: The toxicophore present in mubritinib and CAI is required for efficacy as an 703 
anti-cancer agent 704 
A and B) HL60 cells grown in media containing galactose (A) or glucose (B) as an energy 705 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 706 
μM) or 11 (5 μM) for 72 hours. The percentage of live cells was assessed by DRAQ7™ 707 
staining and Annexin-V-FITC labelling. Error bars represent standard deviation (n = 3) and 708 
significance relative to the untreated control sample was assessed using ANOVA with 709 
Dunnett’s multiple comparisons test (**** p < 0.0001, ns = not significant). 710 
C and D) M059K cells grown in media containing galactose (C) or glucose (D) as an energy 711 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 712 
μM) or 11 (5 μM) for 72 hours. The percentage of live cells was assessed by DRAQ7™ 713 
staining and Annexin-V-FITC labelling. Error bars represent standard deviation (n = 3) and 714 
significance relative to the untreated control sample was assessed using ANOVA with 715 
Dunnett’s multiple comparisons test (**** p < 0.0001, ns = not significant). 716 
E and F) A549 cells grown in media containing galactose (E) or glucose (F) as an energy 717 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 718 
μM) or 11 (5 μM) for 72 hours. The percentage of live cells was assessed by DRAQ7™ 719 
staining and Annexin-V-FITC labelling. Error bars represent standard deviation (n = 3) and 720 
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significance relative to the untreated control sample was assessed using ANOVA with 721 
Dunnett’s multiple comparisons test (**** p < 0.0001, ns = not significant). 722 
G) Cell proliferation profiles from xCELLigence RTCA DP instrument. BT474 cells grown 723 
in glucose containing media were seeded in an E-plate 16 and after 24 hours were treated 724 
with either 5 μM mubritinib (1) or the derivative compound 5 which contains a modified 725 
triazole ring. The cell index was monitored for 96 hours to determine cell proliferation rates. 726 
Error bars represent standard deviation (n = 3). 727 
H) Cell proliferation profiles from xCELLigence RTCA DP instrument. A549 cells grown in 728 
glucose containing media were seeded in an E-plate 16 and after 20 hours were treated with 729 
either 5 μM CAI (9) or the derivative compound 11 which contains a modified triazole ring. 730 
The cell index was monitored for 120 hours to determine cell proliferation rates. Error bars 731 
represent standard deviation (n = 3). 732 
Figure 5: Schematic diagram to show the cell-wide effect of ETC complex I inhibition 733 
by the toxicophore 734 
Chemical inhibition of mitochondrial respiratory complex I with mubritinib and CAI leads to 735 
a decrease in cellular ATP and the subsequent activation of the energy sensor AMPK. 736 
Importantly, AMPK has been shown to phosphorylate and inhibit HER2 41, suggesting how 737 
mubritinib has been misattributed as a HER2 inhibitor, as well to negatively regulate protein 738 
synthesis via the mTOR axis to inhibit tumour cell growth. Moreover, cancer cells that are 739 
dependent on oxidative phosphorylation for ATP production, such as in AML, will be more 740 
sensitive to compounds that inhibit complex I. However, the decrease in ATP levels 741 
following treatment with these compounds will also have a particularly toxic effect on tissues 742 
with a high energy demand, such as cardiac tissue, and thus impact on heart function. 743 
 744 
Supplementary Figure Legends 745 
Figure 1-figure supplement 1: Mubritinib targets complex I in cardiomyocytes 746 
A) Quantification of HER2 phosphorylation from Figure 1A displayed relative to the 747 
untreated sample. Error bars represent standard deviation (n = 3) and significance was 748 
assessed using unpaired students t-test (**** p < 0.0001, ** p < 0.01, * p < 0.05, ns = not 749 
significant). 750 
B) Schematic to show the key components in the signalling pathway that is downstream from 751 
changes in energy status or inhibition of HER2. Arrows indicate activation and blocked 752 
arrows indicate inactivation of the downstream target. 753 
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C) Quantification of (i) ACC (S-79) and (ii) RPS6 (S-240/244) phosphorylation from Figure 754 
1B displayed relative to the untreated sample. Error bars represent standard deviation (n = 3) 755 
and significance was assessed using the unpaired students t-test (* p <0.05, ** p <0.01, *** p 756 
< 0.001, ns = not significant). 757 
Figure 2-figure supplement 1: Mubritinib inhibits OCR in H9c2 and hESC-CM 758 
A and B) Representative seahorse trace (for Figure 2B) from (A) H9c2 or (B) hESC-CM 759 
cells in glucose containing media and treated with mubritinib (1 μM) or oligomycin A (1 760 
μM).  761 
Figure 2-figure supplement 2: Complex I inhibition by mubritinib and the synthesised 762 
variant compounds 763 
A) Mubritinib and the compound variants (i-viii) were incubated with mitochondrial 764 
membranes at the concentrations shown. The rate of NADH oxidation was measured 765 
spectrophotometrically, and data were fit to the standard dose-effect relationship (activity (%) 766 
= 100 / (1 + (IC50 / [inhibitor])Hill slope). The activity is expressed relative to the DMSO 767 
control, set to 100%. For each compound the IC50 values (nM) measured on mitochondrial 768 
membranes are shown with standard errors (n = 3). 769 
Figure 3-figure supplement 1: The toxicophore in CAI inhibits mitochondrial complex I  770 
A and B) Representative seahorse trace (for Figure 3C) of H9c2 cells grown in glucose 771 
containing media and treated with either (A) 3 μM or (B) 10 μM of the indicated compounds.  772 
C) A549 cells were treated with 6 or 12 μM of CAI (9) or compound 10 and compound 11 in 773 
glucose containing media and after 24 hours ATP levels were measured and normalised to the 774 
untreated control. Error bars represent standard deviation (n = 3).  775 
D) Representative seahorse trace (for Figure 3E) of A549 cells grown in glucose containing 776 
media and treated with 5 μM of either CAI (9), 10, 11; or 5 μM mubritinib.  777 
Figure 3-figure supplement 2: Complex I inhibition by mubritinib and the synthesised 778 
variant compounds 779 
A) CAI and the compound variants (i-v) were incubated with mitochondrial membranes at 780 
the concentrations shown. The rate of NADH oxidation was measured 781 
spectrophotometrically, and data were fit to the standard dose-effect relationship (activity (%) 782 
= 100 / (1 + (IC50 / [inhibitor])Hill slope). The activity is expressed relative to the DMSO 783 
control, set to 100%. For each compound the IC50 values (nM) measured on mitochondrial 784 
membranes are shown with standard errors (n = 3). 785 
Figure 3-figure supplement 3: CAI inhibits signalling pathways responsive to changes in 786 
energy status 787 
 30 
A) Western blot analysis of A549 cells treated with 5 μM of CAI (9), 5 μM of 11 (inactive 788 
CAI derivative), 2.5 μM bepridil hydrochloride (non-specific calcium channel inhibitor) or 1 789 
μM rotenone (complex I inhibitor) for 24 hours.  790 
B) Quantification of (i) ACC (S-79) and (ii) RPS6 (S-240/244) phosphorylation from (E) 791 
displayed relative to the untreated sample. Error bars represent standard deviation (n = 3). 792 
Figure 4-figure supplement 1: CAI and mubritinib inhibit cell growth and induce 793 
apoptosis in glycolytic-deficient tumour cell lines. 794 
A and B) HL60 cells grown in media containing galactose (A) or glucose (B) as an energy 795 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 796 
μM) or 11 (5 μM). Cells were harvested at the indicated time points and the percentage of 797 
live cells assessed by DRAQ7™staining and Annexin-V-FITC labelling. Error bars represent 798 
standard deviation (n = 3). 799 
C and D) M059K cells grown in media containing galactose (C) or glucose (D) as an energy 800 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 801 
μM) or 11 (5 μM). Cells were harvested at the time points shown and the percentage of live 802 
cells assessed by DRAQ7™staining and Annexin-V-FITC labelling. Error bars represent 803 
standard deviation (n = 3). 804 
E and F) A549 cells grown in media containing galactose (E) or glucose (F) as an energy 805 
source treated with mubritinib (1) (2 μM), CAI (9) (5 μM) or the inactive derivatives 5 (2 806 
μM) or 11 (5 μM). Cells were harvested at the time points shown and the percentage of live 807 
cells assessed by DRAQ7™staining and Annexin-V-FITC labelling. Error bars represent 808 
standard deviation (n = 3). 809 
G) U-20S (i) cells and HeLa (ii) cells were treated with mubritinib (1) (2 μM), CAI (9) (5 810 
μM) or the inactive derivatives compound 5 (2 μM) or compound 11 (5 μM) in media 811 
containing glucose as an energy source. Cells were harvested at the time points shown and 812 
the percentage of live cells assessed by DRAQ7™staining and Annexin-V-FITC labelling.  813 
H) U-20S (i) cells and HeLa (ii) cells were treated with mubritinib (1) (2 μM), CAI (9) (5 814 
μM) or the inactive derivatives compound 5 (2 μM) or compound 11 (5 μM) in media 815 
containing galactose as an energy source. Cells were harvested at the time points shown and 816 
the percentage of live cells assessed by DRAQ7™staining and Annexin-V-FITC labelling. 817 
 818 
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Supplementary Files 820 
Supplementary File 1: Identification of compounds which contain a non-fused triazole 821 
in a conformation similar to mubritinib 822 
ChEMBL was searched for drugs containing a non-fused triazole, which led to the 823 
identification of a number of small molecules that are used clinically either routinely or in 824 
trials use e.g. the antibiotic tazobactam, the anti-epileptic drug rufinamide, and the cancer 825 
chemotherapeutic carboxyamidotriazole. These all contain the triazole ring, but have 826 
differing associated physicochemical properties.  827 
Supplementary File 2: Ion channel binding assay 828 
The Ca2+ ion channel binding assay to test the activity of CAI (9), 10, 11, mubritinib (1) and 829 
6 was performed by Eurofins. The percentage inhibition of ion channel was calculated 830 
relative to the positive control (1,4,5-IP3). On the scale used a score of 1 = no binding and a 831 
score of 100 = binding. The data show that there is no direct binding of these drugs to the ion 832 
channels.  833 
Supplementary File 3: Ketoconazole, terconazole and rufinamide all contain a heterocyclic 834 
1,3-nitrogen motif.  The compounds listed were incubated with mitochondrial membranes 835 
and the rate of NADH oxidation was measured spectrophotometrically.  836 
 837 
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Appendix 1 1 
 2 
Synthesis of Mubritinib and Carboxamidotriazole (CAI) Analogues 3 
 4 
General Chemistry: Materials and Methods. Chemicals and solvents of analytical and HPLC 5 
grade were purchased from commercial suppliers and used without further purification. All 6 
reactions were carried out at ambient temperature unless otherwise stated. Reactions were 7 
monitored by thin-layer chromatography on commercially available silica pre-coated 8 
aluminium-backed plates (Merck Kieselgel 60 F254). Visualisation was under UV light (254 9 
nm and 366 nm), followed by staining with ninhydrin or KMnO4 dips. Flash column 10 
chromatography was performed using silica gel 60, 230-400 mesh particle size (Sigma 11 
Aldrich). NMR spectra were recorded on a Bruker-AV 400. 1H spectra were recorded at 12 
400.13 Hz and 13C NMR spectra at 101.62 Hz. All 13C NMR are 1H broadband decoupled. 13 
Solvents used for NMR analysis (reference peaks listed) were CDCl3 supplied by Cambridge 14 
Isotope Laboratories Inc., (δH = 7.26 ppm, δC = 77.16) and CD3OD supplied by VWR (δH = 15 
3.31 ppm and δC = 49.00). Chemical shifts (δ) are recorded in parts per million (ppm) and 16 
coupling constants are recorded in Hz. The following abbreviations are used to described 17 
signal shapes and multiplicities; singlet (s), doublet (d), triplet (t), quartet (q), broad (br), dd 18 
(doublet of doublets), ddd (double doublet of doublets), dtd (double triplet of doublets) and 19 
multiplet (m). Spectra were assigned using appropriate COSY and HSQC experiments. 20 
Processing of the NMR data was carried out using the NMR software Topspin 3.0. LC-MS 21 
spectra were recorded on a Shimadzu UFLCXR system coupled to an Applied Biosystems 22 
API2000 and visualised at 254 nm (channel 1) and 220 nm (channel 2). LC-MS was carried 23 
out using a Phenomenex Gemini-NX C18 110A, column (50 mm × 2 mm x 3 μm) at a flow 24 
rate 0.5 mL/min over a 5 min period (Method A). All high-resolution mass spectra (HRMS) 25 
were recorded on a Bruker microTOF mass spectrometer using MS electrospray ionization 26 
operating in positive ion mode. RP-HPLC was performed on a Waters 515 LC system and 27 
monitored using a Waters 996 photodiode array detector at wavelengths between 190 and 28 
800 nm. Spectra were analysed using Millenium 32 software. Analytical RP-HPLC was 29 
performed using a YMC-Pack C8 column (150 mm × 4.6 mm × 5 μm) and a Phenomenex 30 
Gemini NX-C18 column (250 mm × 4.6 mm × 5 μm) at a flow rate of 1.0 mL/min. Final 31 
products were one single peak and >95% pure. The retention time of the final product is 32 
reported using a gradient method of 5-95% solvent B in solvent A over 25 minutes. (Solvent 33 
A = 0.01% formic acid in H2O, solvent B = 0.01% formic acid in CH3CN). 34 
 35 
Abbreviations; DCM, dichloromethane; DIAD, diisopropylazodicarboxylate; DMF, N,N-36 
dimethylformamide; THF, tetrahydrofuran.   37 
 38 
 39 
 40 
 41 
 S2 
 42 
 43 
Mubritinib Analogues (Appendix Figure 1) 44 
 45 
 46 
 47 
Scheme 1. Reagents & Conditions: (a) Tosyl chloride, triethylamine, CH2Cl2, 0℃ → r.t., 20 h; (b) 1H-1,2,3-triazole, NaOH, 48 
NaI, amyl alcohol, Δ, 5h; (c)  pyridine hydrochloride, MW (180 ℃) 2 min then 6 min; (d) PPh3, DIAD, 1H-1,2,3-triazole, THF, 49 
19 h; (e) pyridine hydrochloride, MW (180 ℃) 3 x 2 min; (f) CBr4, PPh3, CH2Cl2, 18 h; (g) Imidazole, NaH, DMF, 18 h; (h) 50 
pyridine hydrochloride, MW (180 ℃) 6 min. 51 
 52 
 53 
 54 
Scheme 2. Reagents & Conditions: (a) (i) (COCl2), DMF, THF, (ii) NH3, H2O, EtOAc; (b) 1,3-dichloroacetone, toluene, Δ; (c) 4-55 
hydroxytoluene, NaH, DMF; (d) 4-substituted phenol (cmpds 15, 18, 22 or 23), NaH, DMF. 56 
 57 
2-(4-(4-methoxyphenyl)butyl)-2H-1,2,3-triazole (14) 58 
To 4-(4’-methoxyphenyl)-1-butanol (13) (0.20 g, 1.1 mmol, 1.0 eq) in THF (7.0 mL), 59 
triphenylphosphine (0.29 g, 1.1 mmol, 1.0 eq) was added. The mixture was stirred for 5 60 
minutes and DIAD (0.27 g, 1.2 mmol, 1.1 eq) was then added. The solution was stirred for a 61 
further 5 minutes and 1H-triazole (84.0 mg, 1.2 mmol, 1.1 eq) was added.  After stirring for 62 
19 hours the THF was removed in vacuo. The residue was purified by column 63 
chromatography (1:9 EtOAc/pet. ether) to afford a pale-yellow oil (0.127 g, 49%). 1H NMR 64 
(400MHz, CDCl3): δ = 7.58 (s, 2H), 7.06 (d, J = 8.6 Hz), 6.81 (d, J = 8.7 Hz), 4.45 (t, J = 7.08 Hz, 65 
2H), 3.78 (s, 3H), 2.58 (t, J = 7.71 Hz, 2H), 1.98 (quintet,  J = 7.4 Hz, 2H), 1.64 – 1.54 (m, 2H). 66 
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13C NMR (100 MHz, CDCl3): δ = 157.96, 133.99, 129.37, 113.92, 55.39, 54.79, 34.39, 29.35, 67 
28.54.  LC-MS m/z calc. for C13H17N3O [MH]
+; 232.1, found; 232.2, tR = 2.81 min. 68 
 69 
2-(4-(4-hydroxyphenyl)butyl)-2H-1,2,3-triazole (15)  70 
To a microwave vial 14 (0.51 g, 2.2 mmol, 1.0 eq) and pyridine hydrochloride (1.27 g, 1.1 71 
mmol, 5.0 eq) were added. The mixture was heated to 180°C in the microwave for 2 72 
minutes. This was repeated twice until all starting material was consumed. The brown solid 73 
obtained was partitioned between EtOAc and water, and the organic layer was washed a 74 
further two times with water and then dried over Na2SO4. The solvent was removed to 75 
afford a brown oil, which was purified by column chromatography (2:8 EtOAc/pet. ether) to 76 
afford the title compound as a dark yellow oil (0.33 g, 69%). 1H NMR (400MHz, CDCl3): δ = 77 
7.59 (s, 2H), 6.99 (d, J = 8.5 Hz), 6.72(d, J = 8.5 Hz), 5.51 (s, 2H), 4.45 (t, J = 7.1 Hz, 2H), 2.55 78 
(t, J = 7.6 Hz, 2H), 1.97 (quintet, J = 7.4 Hz), 1.62 – 1.52 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 79 
= 153.9, 134.04, 133.97, 129.56, 115.34, 54.83, 34.40, 29.35, 28.53. LC-MS m/z calc. for 80 
C12H15N3O [MH]
+; 218.1, found; 218.2, tR = 2.54 min. 81 
 82 
4-(4-methoxyphenyl)butyl 4-methylbenzenesulfonate (16) 83 
To 4-(4’-methoxyphenyl)-1-butanol (13) (2.00 g, 11.10 mmol, 1.0 eq) in CHCl3 (30 mL) at 0°C, 84 
triethylamine (2.25 g, 22.2 mmol, 2.0 eq) and tosyl chloride (3.17 g, 16.6 mmol, 1.5 eq) were 85 
added. The reaction mixture was warmed to room temperature and left to stir for 20 hours. 86 
Sat. NaHCO3(aq) was added and the organic layer was washed again with Sat. NaHCO3(aq) 87 
and brine and then dried over MgSO4. The solvent was removed in vacuo and the orange 88 
residue purified by column chromatography (1:9 EtOAc/pet. ether) to afford the title 89 
compound as a colourless oil (2.69 g, 72%). 1H NMR (400MHz, CDCl3): δ = 7.78 (d, J = 8.3 Hz, 90 
1H), 7.33 (d, J = 7.9 Hz, 1H), 7.02 (d, J = 8.6 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 4.03 (t, J = 6.1 Hz, 91 
1H), 3.78 (s, 3H) 2.50 (t, J = 7.2 Hz, 1H) 2.44 (s, 3H), 1.71-1.56 (m, 4H). 13C NMR (100 MHz, 92 
CDCl3):  δ = 157.98, 144.79, 133.77, 133.36, 129.95, 129.36, 128.01, 113.92, 77.48, 77.36, 93 
77.16, 76.84, 70.57, 55.40, 34.30, 28.43, 27.43, 21.77. LC-MS m/z calc. for C18H23O4S [MH]
+; 94 
335.1, found; 335.1, tR = 3.12 min. 95 
 96 
1-(4-(4-methoxyphenyl)butyl)-1H-1,2,3-triazole (17)  97 
To 1H-1,2,3-triazole (0.225 g, 3.26 mmol, 1.0 eq) in amyl alcohol (45.0 mL) NaOH (0.130 g, 98 
3.26 mmol, 1.0 eq) and NaI (0.489 g, 3.26 mmol, 1.0 eq) were added. The mixture was 99 
heated to reflux for 1 hour and 16 (1.200 g, 3.59 mmol, 1.1 eq) in amyl alcohol (5.0 mL) was 100 
added over 10 mins. After a further 5 hours at reflux the solvent was removed and the 101 
residue partitioned between toluene and water. The organic layer was washed with sat. 102 
NaHCO3(aq) and brine and dried over MgSO4. The solvent was removed in vacuo and the 103 
crude product purified by column chromatography (1:1 EtOAc/pet.ether). The title 104 
compound was afforded as a pale-yellow oil (0.521 g, 48%). 1H NMR (400 MHz, CDCl3): δ 105 
7.69 (d, J = 0.9 Hz, 1H), 7.50 (d, J = 0.9 Hz, 1H), 7.05 (d, J = 8.6 Hz, 2H), 6.82 (d, J = 8.6 Hz, 106 
2H), 4.38 (t, J = 7.2 Hz, 2H), 3.78 (s, 3H), 2.59 (t, J = 7.5 Hz, 2H), 2.02 – 1.82 (m, 2H), 1.75 – 107 
 S4 
1.52 (m, 2H). 13C NMR (101 MHz, CDCl3): δ = 158.06, 133.76, 133.56, 129.37, 123.33, 108 
114.00, 55.40, 50.23, 34.34, 29.83, 28.47.LC-MS m/z calc. for C13H17N3O [MH]
+; 231.1, 109 
found; 231.9, tR = 2.68 min. 110 
1-(4-(4-hydroxyphenyl)butyl)-1H-1,2,3-triazole (18) 111 
To a microwave vial 17 (0.46 g, 1.99 mmol, 1.0 eq) and pyridine hydrochloride (1.15 g, 9.94 112 
mmol, 5.0 eq) were added. The mixture was heated to 180°C in the microwave for 6 113 
minutes and then a further 2 minutes. The brown solid obtained was partitioned between 114 
EtOAc and water, and the organic layer was washed a further two times with water and 115 
then dried over Na2SO4. The solvent was removed to afford a brown oil, which was purified 116 
by column chromatography (2:98 MeOH/DCM) to afford the title compound as a pale yellow 117 
solid (0.151 g, 35 %). 1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.10 (d, J = 0.9 Hz, 1H), 118 
7.70 (d, J = 0.9 Hz, 1H), 6.94 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 4.38 (t, J = 7.1 Hz, 2H), 119 
2.47 (t, J = 7.6 Hz, 2H), 1.79 (p, J = 7.2 Hz, 2H), 1.44 (p, J = 7.7 Hz, 1H). 13C NMR (101 MHz, 120 
DMSO-d6) δ 155.29, 133.11, 131.71, 129.02, 124.56, 115.00, 48.91, 33.51, 29.33, 28.07. LC-121 
MS m/z calc. for C12H15N3O [MH]
+; 218.1, found; 217.9, tR = 2.39 min. 122 
 123 
4-(4-methoxyphenyl)-1-butyl bromide (19) 124 
To 4-(4’-methoxyphenyl)-1-butanol (13) (0.500 g, 2.78 mmol, 1.0 eq) and carbon 125 
tetrabromide (1.021 g, 3.05 mmol, 1.1 eq) in DCM (7.0 mL), triphenylphosphine (0.582 g, 126 
2.22 mmol, 0.8 eq) was added. The mixture was stirred at room temperature overnight and 127 
the solvent was removed in vacuo. The crude orange residue was purified by column 128 
chromatography on silica (100 % pet. ether to 1:4 EtOAc/pet. ether) to afford a colourless 129 
oil (0.335 g, 50 %). 1H NMR (400MHz, CDCl3): δ = 7.10 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.6 Hz, 130 
2H), 3.79 (s, 3H), 3.42 (t, J = 6.7 Hz, 2H), 2.59 (t, J = 7.5 Hz, 2H), 1.95 – 1.83 (m, 2H), 1.82 – 131 
1.68 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 157.98, 134.00, 129.39, 113.94, 55.41, 34.20, 132 
33.84, 32.36, 30.22. LC-MS m/z calc. for C11H15BrO [MH]
+; 242.0, found; did not ionise, tR = 133 
3.23 min. 134 
 135 
1-(4-(4-methoxyphenyl)butyl)-1H-imidazole (20)   136 
To 1I-imidazole (0.134 g, 1.97 mmol, 1.0 eq) in anhydrous DMF (2.0 mL) under nitrogen and 137 
with ice cooling, sodium hydride (0.079 g, 1.97 mmol, 1.0 eq) was added. The mixture was 138 
stirred for 30 minutes and 19 (0.480 g, 1.97 mmol, 1.0 eq) in DMF (2.0 mL) was added with 139 
ice cooling. The reaction mixture was stirred for a further 18 hours and then quenched with 140 
water. The solvent was removed under vacuum and the residue purified by column 141 
chromatography on silica (5:95 MeOH/DCM) to afford the title product as a pale-yellow oil 142 
(0.310 g, 68%). 1H NMR (400 MHz, CDCl3): δ 7.43 (s, 1H), 7.07 – 7.02 (m, 3H), 6.87 (t, J = 1.3 143 
Hz, 1H), 6.82 (d, J = 8.6 Hz, 2H), 3.91 (t, J = 7.1 Hz, 2H), 3.78 (s, 3H), 2.57 (t, J = 7.5 Hz, 2H), 144 
1.85 – 1.71 (m, 2H), 1.63 – 1.53 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 158.03, 137.16, 145 
133.66, 129.54, 129.35, 118.88, 113.98, 55.40, 47.03, 34.48, 30.65, 28.60. LC-MS m/z calc. 146 
for C14H18N2O [MH]
+; 230.1, found; 230.8, tR = 1.99 min. 147 
 148 
 S5 
1-(4-(4-methoxyphenyl)butyl)-1H-pyrrole (21)  149 
To pyrrole (0.135 g, 2.02 mmol, 1.0 eq) in anhydrous DMF (2.0 mL) under nitrogen and with 150 
ice cooling, sodium hydride (0.081 g, 2.02 mmol, 1.0 eq) was added. The mixture was stirred 151 
for 30 minutes and 19 (0.490 g, 1.97 mmol, 1.0 eq) in DMF (2.0 mL) was added with ice 152 
cooling. The reaction mixture was stirred for a further 18 hours and then quenched with 153 
water. The solvent was removed under vacuum and the residue was purified by column 154 
chromatography on silica (5:95 MeOH/DCM) to afford the title product as a colourless oil 155 
(0.189 g, 41%). 1H NMR (400 MHz, CDCl3): δ 7.07 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 156 
6.64 (t, J = 2.1 Hz, 2H), 6.14 (t, J = 2.1 Hz, 2H), 3.88 (t, J = 7.1 Hz, 2H), 3.80 (s, 3H) 2.57 (t, J = 157 
7.6 Hz, 2H), 1.89 – 1.74 (m, 2H), 1.67 – 1.56 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 157.93, 158 
134.13, 129.39, 120.59, 113.90, 107.97, 55.40, 49.62, 34.64, 31.19, 28.86. LC-MS m/z calc. 159 
for C15H19NO [MH]
+; 229.1, found; 230.1, tR = 3.15 min. 160 
 161 
1-(4-(4-hydroxyphenyl)butyl)-1H-imidazole  (22)  162 
To a microwave vial 20 (0.21 g, 0.89 mmol, 1.0 eq) and pyridine hydrochloride (0.51 g, 4.45 163 
mmol, 5.0 eq) were added. The mixture was heated to 180°C in the microwave for 6 164 
minutes. The brown solid obtained was partitioned between EtOAc and water. The organic 165 
layer was washed twice with water and then dried over Na2SO4. As some product remained 166 
in the aqueous layer it was basified to pH8 and re-extracted with EtOAc. The solvent was 167 
removed to afford a brown solid, which was purified by column chromatography (5:95 168 
MeOH/DCM) to afford the title compound as a white solid (98.6 mg, 51%). 1H NMR (400 169 
MHz, CDCl3): δ = 7.47 (s, 1H), 7.07 (s, 1H), 6.95 (d, J = 8.4 Hz, 2H), 6.88 (s, 1H), 6.79 (d, J = 8.5 170 
Hz, 2H), 3.92 (t, J = 7.0 Hz, 2H), 2.54 (t, J = 7.4 Hz, 2H), 1.79 (p, J = 7.1 Hz, 2H), 1.55 (p, J = 7.6 171 
Hz, 2H). 13C NMR (101 MHz, CDCl3): δ = 155.62, 136.80, 132.34, 129.37, 128.74, 119.12, 172 
115.74, 77.48, 77.36, 77.16, 76.84, 47.26, 34.49, 30.41, 28.55. LC-MS m/z calc. for C13H17N2O 173 
[MH]+; 217.2, found, 217.3 tR = 1.02 min. 174 
 175 
1-(4-(4-hydroxyphenyl)butyl)-1H-pyrrole (23) 176 
To a microwave vial 21 (0.14 g, 0.61 mmol, 1.0 eq) and pyridine hydrochloride (0.35 g, 3.05 177 
mmol, 5.0 eq) were added. The mixture was heated to 180°C in the microwave for 6 178 
minutes. The brown solid obtained was partitioned between EtOAc and water, and the 179 
organic layer was washed twice with water and then dried over Na2SO4. The solvent was 180 
removed to afford a brown oil, which was purified by column chromatography (1:9 to 2:8 181 
EtOAc/pet. ether) to afford the title compound as a colourless oil (81.9 mg, 63%). 1H NMR 182 
(400MHz, CDCl3): δ = 7.01 (d, J = 8.7 Hz, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.64 (t, J = 2.1 Hz, 2H), 183 
6.14 (t, J = 2.1 Hz, 2H), 3.87 (t, J = 7.1 Hz, 2H), 2.55 (t, J = 7.6 Hz, 2H), 1.84-1.73 (m, 2H), 1.61 184 
– 1.53 (m, 2H). 13C NMR (100 MHz, CDCl3): δ = 153.76, 134.27, 129.57, 120.60, 115.29, 185 
107.98, 77.47, 77.36, 77.16, 76.84, 49.61, 34.64, 31.16, 28.84. m/z calc. for C14H18NO [MH]
+; 186 
216.2, found; 216.1, tR = 2.89. 187 
 188 
 189 
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Synthesis of propenamides (28-31)  190 
General method A with (E)-3-phenyl-2-propenamide (31) as an example.  191 
To trans-cinnamic acid (27) (1.0 g, 6.8 mmol, 1.0 eq) in THF (10 mL) at 0°C under nitrogen, 192 
DMF (1 drop) and oxalyl chloride (1.0 g, 8.1 mmol, 1.2 eq) were added. The mixture was 193 
stirred at room temperature for 2 hours and further oxalyl chloride (0.5 eq) was added. The 194 
solvent was removed in vacuo and the resulting oil dissolved in EtOAc (5 mL) and added 195 
dropwise to a stirred mixture of 35% NH4OH(aq) (5.0 mL) and EtOAc (2.0 mL) at 0°C. The 196 
resulting white needle-like crystals were recovered by vacuum filtration and washed with 197 
water and petroleum ether to afford the title compound (0.891 g, 90%).  1H NMR (400MHz, 198 
DMSO-d6): δ = 7.59 – 7.52 (m, 3H), 7.47 - 7.33 (m, 4H), 7.13 (broad s, 1H), 6.62 (d, J = 15.9 199 
Hz, 1H). 13C NMR (100 MHz, DMSO-d6): δ = 166.68, 139.15, 134.88, 129.42, 128.90, 127.52, 200 
122.34.  LC-MS m/z calc. for C9H9NO [MH]
+; 148.1, found; 148.1, tR = 2.18 min. 201 
 202 
(E)-3-(4-methylphenyl)-2-propenamide (28) 203 
Compound 28 was prepared according to the procedure described in general method A 204 
using (E)-3-(p-tolyl)acrylic acid (24) as starting material. White solid (0.831 g, 84%). 1H NMR 205 
(400MHz, DMSO-d6): δ = 7.51 (broad s, 1H), 7.45 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 15.9 Hz, 1H), 206 
7.21 (d, J = 7.9 Hz, 2H), 7.08 (broad s, 1H), 6.56 (d, J = 15.9 Hz, 1H), 2.31 (s, 3H). 13C NMR 207 
(100 MHz, DMSO-d6): δ = 166.83, 139.15, 139.09, 132.13, 129.49, 127.79, 121.29, 20.91. LC-208 
MS m/z calc. for C10H12NO [MH]
+; 162.1, found; 162.2, tR = 2.35 min. 209 
 210 
(E)-3-(4-methoxyphenyl) propenamide (29) 211 
Compound 29 was prepared according to the procedure described in general method A 212 
using (E)-3-(4-methoxyphenyl)acrylic acid (25) as starting material. White solid (0.833 g, 213 
84%). 1H NMR (400MHz, DMSO-d6): δ = 7.49 (d, J = 8.8 Hz, 2H), 7.46 (broad s, 1H), 7.37 (d, J 214 
= 15.8 Hz, 1H), 7.01 (broad s, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.47 (d, J = 15.9 Hz 1H), 3.78 (s, 215 
3H). 13C NMR (100 MHz, DMSO-d6): δ = 167.00, 160.31, 138.88, 129.09, 127.43, 119.81, 216 
114.36, 55.23. LC-MS m/z calc. for C10H11NO2 [MH]
+; 178.1, found; 178.2, tR = 2.21 min. 217 
 218 
(E)-3-(4-trifluoromethylphenyl)-2-propenamide (30) 219 
Compound 30 was prepared according to the procedure described in general method A 220 
using (E)-3-(4-trifluoromethylphenyl)acrylic acid (26) as starting material. White solid (0.850 221 
g, 85%). 1H NMR (400MHz, DMSO-d6): δ = 7.72 (m, 4H), 7.63 (broad s, 1H), 7.49 (d, J = 15.9 222 
Hz, 1H), 7.24 (broad s, 1H), 6.75 (d, J = 15.9 Hz, 1H).  13C NMR (100 MHz, DMSO-d6): δ = 223 
166.18, 138.97, 129.20 (q, J = 31.8 Hz), 128.14, 125.74 (q, J = 3.8 Hz), 125.18, 122.73 (q, J = 224 
272.1 Hz). LC-MS m/z calc. for C10H9F3NO [MH]
+; 216.0, found; 216.2, tR = 2.62 min. 225 
 226 
 227 
 228 
 229 
 230 
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Synthesis of oxazole intermediates (32-35) 231 
General method B with 4-chloromethyl-2-[(E)-2-phenylethenyl]-oxazole (35) as an 232 
example.   233 
To 31 (0.500g, 3.39 mmol, 1.0 eq) in toluene (5.0 mL), 1,3-dichloroacetone (0.431g 3.39 234 
mmol, 1.0 eq) was added. The mixture was stirred at reflux for 4.5 hours and after cooling 235 
was poured onto sat. K2CO3(aq). The aqueous layer was extracted with EtOAc and the 236 
combined organic layers were washed with water, brine, and then dried over Na2SO4. The 237 
crude product was then purified by column chromatography (1:9 EtOAc/pet. ether) to 238 
afford the title product as a white crystalline solid (0.323g, 43%). 1H NMR (400MHz, CDCl3): 239 
δ = 7.62 (s, 1H), 7.58–7.50 (m, 3H), 7.43–7.31 (m, 3H), 6.92 (d, J = 16.37, 1H), 4.54 (d, J = 0.8 240 
Hz, 2H). 13C NMR (100 MHz, CDCl3): δ = 162.49, 139.14, 137.43, 136.10, 135.61, 129.76, 241 
129.26, 127.62, 113.79, 37.34.  LC-MS m/z calc. for C12H11
35ClNO [MH]+; 220.1, found; 220.1, 242 
tR = 2.88 min. 243 
 244 
4-chloromethyl-2-[(E)-2-(4-methylphenyl)ethenyl]-1,3-oxazole (32) 245 
Compound 32 was prepared according to the procedure described in general method B 246 
using 28 as starting material. A further 0.5 eq of 1,3-dichloroacetone was added after 24 247 
hours. Column chromatography eluent; 1:9 EtOAc/pet. ether. The title compound was 248 
obtained as a white solid (0.444 g, 61%). 1H NMR (400MHz, CDCl3): δ = 7.61 (s, 2H), 7.51 (d, J 249 
= 16.4 Hz, 1H), 7.42 (d,  J = 8.1 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 6.87 (d, J = 16.4 Hz, 1H), 4.53 250 
(d, J = 0.8 Hz, 2H), 2.37 (s, 3H).  13C NMR (100 MHz, CDCl3): δ = 162.51, 139.83, 138.84, 251 
137.21, 135.74, 132.67, 129.77, 127.34, 112.56, 37.18, 21.53.  LC-MS m/z calc. for 252 
C13H13
35ClNO [MH]+; 234.1 found; 234.4, tR = 3.09 min. 253 
 254 
4-chloromethyl-2-[(E)-2-(4-methoxyphenyl)ethenyl]-1,3-oxazole (33) 255 
Compound 33 was prepared according to the procedure described in general method B 256 
using 29 as starting material. Column chromatography eluent; 1:9 EtOAc/pet. ether. The 257 
title compound was obtained as a pale yellow solid (0.238 g, 34%). 1H NMR (400 MHz, CDCl3) 258 
δ 7.60 (s, 1H), 7.51 (s, 1H), 7.49 (d, J = 16.3 Hz 7.47 (d, J = 8.5 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 259 
6.78 (d, J = 16.4 Hz, 1H), 4.53 (d, J = 1.0 Hz, 2H), 3.84 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 260 
=162.56, 161.03, 138.95, 137.02, 135.77, 129.07, 128.36, 114.69, 111.52, 55.69, 37.39. LC-261 
MS m/z calc. for C13H13
35ClNO2 [MH]
+; 250.0, found; 250.2, tR = 2.85 min. 262 
 263 
4-chloromethyl-2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazole (34) 264 
Compound 34 was prepared according to the procedure described in general method B 265 
using 30 as starting material. Column chromatography eluent; 1:9 EtOAc/pet. ether. The 266 
title compound was obtained as a white solid (0.359 g, 54%). 1H NMR (400MHz, CDCl3): δ = 267 
7.68 – 7.59 (m, 5H), 7.56 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 16.4 Hz, 1H), 4.54 (d, J = 0.8 Hz, 2H). 268 
13C NMR (100 MHz, CDCl3): δ = 161.63, 139.25, 138.79, 136.33, 135.39, 131.28, 130.95, 269 
127.51, 126.04 (q, J = 3.9 Hz), 124.07 (q, J = 272.24), 115.94, 37.00,  LC-MS: m/z calc. for 270 
C13H10
35ClF3NO [MH]
+; 288.04, found; 287.9,  tR = 3.16 min. 271 
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 272 
4-(4’-methylphenoxymethyl)-2-[(E)-2-(4-trifluoromethylphenyl)ethenyl]-1,3-oxazole (5) 273 
To a solution of 34 (0.12 g, 0.42 mmol, 1.0 eq) in DMF (5.0 mL), sodium hydride (60% in 274 
mineral oil, 17.0 mg, 0.42 mmol, 1.0 eq) was added under N2 with ice cooling. The mixture 275 
was stirred at room temperature for 30 minutes and p-cresol (45.0 mg, 0.42 mmol, 1.0 eq) 276 
was added. The mixture was stirred at room temperature for 23 hours and water (20 mL) 277 
was then added. A precipitate formed which was isolated by vacuum filtration, washed with 278 
water and petroleum ether and was then purified by column chromatography (1:9 279 
EtOAc/pet. ether). The solvent was removed in vacuo to afford the title compound as a 280 
white crystalline solid. 1H NMR (400MHz, CDCl3): 7.67 (s, 1H), 7.67 – 7.59 (m, 4H), 7.54 (d, J 281 
= 16.5 Hz, 1H), 7.10 (d, J = 8.3 Hz, 2H), 7.01 (d, J = 16.4 Hz, 1H), 6.89 (d, J = 8.6 Hz, 2H), 5.02 282 
(d, J = 0.98, 2H), 2.29 (s, 3H) 13C NMR (100 MHz, CDCl3): δ = 161.38, 156.33, 139.03, 138.94, 283 
136.57, 134.92, 130.93 (q, J = 29.1 Hz), 130.12, 127.47, 126.02 (q, J = 3.9 Hz), 121.41 (q, J = 284 
270.9 Hz), 116.18, 114.81, 62.83, 20.64. HRMS: (m/z) calc for C20H16F3NO2 [MH]
+; 360.1206 285 
found; 360.1213. LC-MS m/z calc. for C20H16F3NO2 [MH]
+; 360.1, found; 360.2, tR = 3.35 min. 286 
Analytical RP-HPLC tR = 22.35, 95% purity. 287 
 288 
Synthesis of triazole, pyrrole and imidazole final compounds (1-4 & 6-8)  289 
General method C with (E)-4-((4-(4-(2H-1,2,3-triazol-2-yl)butyl)phenoxy)methyl)-2-(4-290 
(trifluoromethyl)styryl)oxazole (6) as an example 291 
To a solution of 15 (30.0 mg, 0.14 mmol, 1.0 eq) in DMF (2.0 mL), sodium hydride (60% in 292 
mineral oil, (55.0 mg, 0.14 mmol, 1.0 eq) was added with ice cooling under N2. The mixture 293 
was stirred at room temperature for 30 minutes and 34 (39.0 mg, 0.14 mmol, 1.0 eq) was 294 
added with ice cooling. The mixture was stirred at room temperature for 19 hours and 295 
water was then added. A precipitate formed which was isolated by vacuum filtration and 296 
was then purified by column chromatography (2:8 EtOAc/pet. ether). The title compound 297 
was obtained as a white solid (20.0 mg, 31%). 1H NMR (400MHz, CDCl3): δ = 7.67 (s, 1H), 298 
7.66 – 7.59 (m, 4H), 7.54 (d, J = 16.3 Hz, 1H) 7.58 (s, 1H), 7.08 (d, J = 8.6 Hz, 2H), 7.01 (d, J = 299 
16.4 Hz, 1H), 6.91 (d, J = 8.6 Hz, 2H), 5.02 (s, 1H), 5.01 (s, 1H), 4.46 (t, J = 7.0 Hz, 2H), 2.59 (t, 300 
J = 7.6 Hz, 2H), 1.99 (quintet, J = 7.4 Hz, 2H), 1.65 – 1.54 (m, 2H).  13C NMR (100 MHz, CDCl3): 301 
δ = 161.25, 156.56, 138.86, 138.79, 136.44, 134.79, 134.63, 133.89, 130.88 (q, J = 31.1 Hz), 302 
129.34, 127.34, 125.88 (q, J = 3.8 Hz), 123.96 (q, J = 271.6 Hz), 116.05, 114.73, 62.67, 54.66, 303 
34.31, 29.24, 28.36. HRMS: (m/z) calc. for C25H23N4O2 [MH]
+; 469.1846 found; 469.1849. LC-304 
MS m/z calc. for C25H23N4O2 [MH]
+; 469.2, found; 469.2, tR = 3.21 min. Analytical RP-HPLC: tR 305 
= 22.26, Purity = 99%. 306 
 307 
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-((4-trifluoromethyl)styryl)oxa-308 
zole (1) 309 
Compound 1 was prepared according to the procedure described in general method C using 310 
compounds 18 and 34 as starting materials. Column chromatography eluent (1:1 EtOAc/pet. 311 
ether) the title compound was obtained as a white solid (39.0 mg, 60%). 1H NMR (400 MHz, 312 
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DMSO-d6):) δ 8.24 (s, 1H), 8.11 (d, J = 0.9 Hz, 1H), 7.95 (d, J = 8.1 Hz, 2H), 7.76 (d, J = 8.2 Hz, 313 
2H), 7.70 (d, J = 0.9 Hz, 1H), 7.61 (d, J = 16.4 Hz, 1H), 7.34 (d, J = 16.5 Hz, 1H), 7.09 (d, J = 8.6 314 
Hz, 2H), 6.94 (d, J = 8.6 Hz, 2H), 4.98 (d, J = 0.9 Hz, 2H), 4.39 (t, J = 7.1 Hz, 2H), 2.54 (d, J = 7.6 315 
Hz, 2H), 1.81 (m, 2H), 1.60 – 1.39 (m, 2H). 13C NMR (101 MHz, DMSO-d6):) δ = 160.55, 316 
156.18, 139.19, 138.11, 138.08, 134.30, 134.07, 133.12, 129.18, 128.05, 125.63 (q, J = 3.4 317 
Hz), 124.58, 124.11 (q, J = 271.8), 116.42, 114.55, 61.49, 48.88, 33.44, 29.32, 27.96. LC-MS 318 
m/z calc. for C25H23N4O2 [MH]
+; 469.2, found; 469.1, tR = 3.09 min. HRMS: (m/z) calc. for 319 
C25H23N4O2 [MH]
+; 469.1846 found; 469.1853. Analytical RP-HPLC: tR = 20.19 min, purity = 320 
99%. 321 
 322 
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(styryl)oxazole (2) 323 
Compound 2 was prepared according to the procedure described in general method C using 324 
compounds 18 and 35 as starting materials. Column chromatography eluent; 7:3 EtOAc/pet. 325 
ether. The title compound was obtained as an off-white solid (0.05 g, 68%). 1H NMR (400 326 
MHz, CDCl3) δ 7.71 (s, 1H), 7.65 (s, 1H), 7.61 – 7.46 (m, 4H), 7.44 – 7.31 (m, 3H), 7.07 (d, J = 327 
8.3 Hz, 2H), 6.95 (d, J = 16.5 Hz, 1H), 6.92 (d, J = 8.5 Hz, 2H), 5.02 (s, 2H), 4.39 (t, J = 7.1 Hz, 328 
2H), 2.60 (t, J = 7.5 Hz, 2H), 1.94 (m, 2H), 1.63 (m, 2H). 13C NMR (101 MHz, CDCl3) δ = 162.08, 329 
156.79, 138.14, 137.63, 136.27, 135.34, 134.29, 133.59, 129.68, 129.49, 129.07, 127.51, 330 
123.61, 114.99, 113.28, 62.65, 50.48, 34.39, 29.84, 28.43. LC-MS m/z calc. for C24H24N4O2 331 
[MH]+; 401.2, found; 401.1, tR = 3.02 min. HRMS: (m/z) calc. for C24H24N4O2 [MH]
+; 401.1972 332 
found; 401.1976. Analytical RP-HPLC tR = 18.99 min, purity = 98%. 333 
 334 
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-((4-methyl)styryl)oxazole (3) 335 
Compound 3 was prepared according to the procedure described in general method C using 336 
18 and 32 as starting materials. Column chromatography eluent; 8:2 EtOAc/pet. ether. The 337 
title compound was obtained as a white solid (38.0 mg, 50%). 1H NMR (400 MHz, CDCl3): δ 338 
7.70 (s, 1H), 7.64 (s, 1H), 7.53 (d, J = 16.4 Hz, 1H), 7.50 (s, 1H), 7.43 (d, J = 8.0 Hz, 2H), 7.20 339 
(d, J = 7.9 Hz, 2H), 7.07 (d, J = 8.6 Hz, 2H), 6.91 (d, J = 8.6 Hz, 1H), 6.89 (d, J = 16.4 Hz, 1H), 340 
5.01 (d, J = 1.1 Hz, 2H), 4.39 (t, J = 7.2 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 2.38 (s, 3H), 2.05 – 341 
1.87 (m, 2H), 1.75 – 1.52 (m, 2H). 13C NMR (101 MHz, CDCl3): δ = 162.30, 156.79, 140.05, 342 
137.97, 137.77, 136.11, 134.30, 133.66, 132.59, 129.80, 129.47, 127.50, 123.45, 114.98, 343 
112.17, 62.61, 50.35, 34.38, 29.83, 28.42, 21.58. LC-MS m/z calc. for C25H26N4O2 [MH]
+; 344 
415.2, found; 415.1, tR = 3.08 min. HRMS: (m/z) calc. for C25H26N4O2 [MH]
+; 415.2129 found; 345 
415.2132. Analytical RP-HPLC tR = 19.68 min, purity = 97%. 346 
 347 
(E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-((4-methoxy)styryl)oxazole (4) 348 
Compound 4 was prepared according to the procedure described in general method C using 349 
18 and 33 as starting materials. Column chromatography eluent; (8:2 EtOAc/pet. ether) the 350 
title compound was obtained as a white solid (48.4 mg, 81%). 1H NMR (400 MHz, CDCl3): δ 351 
7.69 (d, J = 1.0 Hz, 1H), 7.62 (s, 1H), 7.50 (d, J = 16.6 Hz, 1H), 7.49 (d, J = 1.0 Hz, 1H), 7.48 (d, 352 
J = 8.6 Hz, 2H), 7.06 (d, J = 8.6 Hz, 2H), 6.92 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 6.80 353 
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(d, J = 16.4 Hz, 1H), 5.00 (d, J = 1.1 Hz, 2H), 4.39 (t, J = 7.2 Hz, 2H), 3.84 (s, 3H), 2.60 (t, J = 7.5 354 
Hz, 2H), 1.97-1.90 (m, 2H), 1.67 – 1.56 (m, 2H). 13C NMR (101 MHz, CDCl3): δ 162.47, 355 
160.97, 156.78, 137.87, 137.36, 135.93, 134.30, 133.80, 129.46, 129.04, 128.09, 123.11 (q, J 356 
= 271.8 Hz) 123.35, 114.95, 114.54, 110.90, 62.61, 55.54, 50.25, 34.39, 29.85, 28.43. LC-MS 357 
m/z calc. for C25H23N4O2 [MH]
+; 431.2, found; 431.0, tR = 3.00 min. HRMS: (m/z) calc. for 358 
C25H23N4O2 [MH]
+; 431.2078 found; 431.2079. Analytical RP-HPLC: tR = 18.83 min, purity = 359 
99%. 360 
(E)-4-((4-(4-(1H-imidazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole 361 
(7)  362 
Compound 7 was prepared according to the procedure described in general method C using 363 
22 and 34 as starting materials. Column chromatography eluent; 3:7 EtOAc/pet ether. The 364 
title compound was obtained as a white solid (61.8 mg, 95%). 1H NMR (400MHz, CDCl3): δ = 365 
7.68 (br s, 1H), 7.67-7.59 (m, 4H), 7.55 (d, J = 16.5 Hz, 1H), 7.44 (br s, 1H)7.06 (d, J = 8.6 Hz, 366 
2H), 7.04 (br s, 1H) 7.01 (d, J = 16.4 Hz, 1H), 6.92 (d, J = 8.7 Hz, 3H), 6.87 (br s, 1H), 5.02 (d, J 367 
= 1.0 Hz, 2H), 3.92 (t, J = 7.1 Hz, 2H), 2.58 (t, J = 7.5 Hz, 2H), 1.79 (m, 2H), 1.59 (m, 2H). 13C 368 
NMR (100 MHz, CDCl3): δ = 161.40, 156.77, 138.88, 137.16, 136.59, 134.97, 134.43, 129.52, 369 
129.44, 127.46, 126.00 (q, J = 3.6 Hz), 118.89, 116.13, 114.92, 77.47, 77.36, 77.15, 76.84, 370 
62.76, 47.04, 34.51, 30.64, 28.54. HRMS: (m/z) calc. for C26H24F3N3O2 [MH]
+; 468.1893 371 
found; 468.1914. LC-MS m/z calc. for C26H24F3N3O2 [MH]
+; 468.2, found; 468.3, tR = 2.50 min. 372 
Analytical RP-HPLC: tR = 17.64, purity = 97%. 373 
 374 
(E)-4-((4-(4-(1H-pyrrol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole (8)  375 
Compound 8 was prepared according to the procedure described in general method C using 376 
23 and 34 as starting materials. Column chromatography eluent; 1:9 to 2:8 EtOAc/pet ether. 377 
The title compound was obtained as an off-white solid (55.1 mg, 85%). 1H NMR (400MHz, 378 
CDCl3): δ = 7.68 (s, 1H), 7.64 (m, 4H), 7.55 (d, J = 16.4 Hz, 1H), 7.08 (d, J = 8.6 Hz, 2H), 7.02 379 
(d, J = 16.4 Hz, 1H), 6.91 (d, J = 8.6 Hz, 1H), 6.63 (t, J = 2.1 Hz, 2H), 6.13 (t, J = 2.1 Hz, 2H), 380 
5.02 (d, J = 1.1 Hz, 2H), 3.87 (t, J = 7.1 Hz, 2H), 2.57 (t, J = 7.6 Hz, 2H), 1.88 – 1.71 (m, 2H), 381 
1.65 – 1.57 (m, 1H). 13C NMR (100 MHz, CDCl3): δ = 161.39, 156.67, 138.97, 136.58, 134.95, 382 
134.91, 129.49, 127.47, 126.02 (q, J = 3.6 Hz), 120.60, 116.17, 114.85, 108.00, 77.48, 77.36, 383 
77.16, 76.84, 62.80, 49.62, 34.68, 31.19, 28.80.  HRMS: (m/z) calc. for C27H25F3N2O2 [MH]
+; 384 
467.1941 found; 467.1944. LC-MS m/z calc. for C27H25F3N3O2 [MH]
+; 467.2, found; 467.5, tR = 385 
3.48 min. Analytical RP-HPLC: tR = 23.23, purity = 97%. 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
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 394 
Carboxamidotriazole (CAI) Analogues 395 
 396 
 397 
 398 
Scheme 3. Reagents & Conditions: (a) TBDMSCl, imidazole, DMAP, DMF; (b) (i) nBuLi, THF, -78 ℃, 4-chlorobenzoyl chloride; 399 
(c) TBAF, THF; (d) PBr3, THF; (e) Tosyl chloride, DIPEA, CHCl3; (f) 5-amino-1H-imidazole-4-carboxamide, K2CO3, MeCN; (g) 3-400 
aminopyrazole-carboxamide, NaH, DMF; (h) NaN3, EtOH (i) Cyanoacetamide, EtOH, 30% NaOMe in MeOH. 401 
 402 
tert-butyl((3,5-dichlorobenzyl)oxy)dimethylsilane (37) 403 
To a mixture of 3,5-dibromobenzyl alcohol (36) (3.00 g, 16.9 mmol) and imidazole (2.77 g, 40.7 404 
mmol) in DMF (30 mL), was added tert-butyldimethylsilyl chloride (3.06 g, 20.3 mmol). After stirring 405 
for 1 day at room temperature, the mixture was diluted with ether, washed twice with water and 406 
then dried over MgSO4. Concentration of the organic phase afforded a clear colourless oil (4.94 g, 407 
100%) 1H NMR (400 MHz, Chloroform-d) δ 7.25 – 7.22 (m, 1H), 7.21 – 7.18 (m, 2H), 4.68 (s, 2H), 0.95 408 
(s, 9H), 0.11 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 145.12, 134.93, 127.10, 124.44, 63.88, 26.04, 18.53, 409 
-5.18. 410 
 411 
(4-(((tert-butyldimethylsilyl)oxy)methyl)-2,6-dichlorophenyl)(4-chlorophenyl)methanone (38) 412 
A mixture of 37 (1.00 g, 3.4 mmol) in anhydrous THF (10 mL) was cooled to -72°C in a hexane/dry ice 413 
bath. n-Butyl lithium (2.3M, 1.5 mL, 3.8 mmol) was added dropwise keeping the temperature ≤-60°C. 414 
The mixture was stirred at ≤60°C for 30 minutes and was then cooled to -72°C. Chlorobenzoyl 415 
chloride (0.52 mL, 4.1 mmol) in THF (2 mL) was added dropwise keeping the temperature below -416 
60°C. The mixture was stirred at -60°C for 3 hours and was then quenched with 2M HCl(aq) (2 mL) and 417 
allowed to warm to room temperature. The THF was removed under vacuum and the residue was 418 
partitioned between EtOAc and water. The organic layer was washed with sat. NaHCO3, brine and 419 
then dried over MgSO4. The solvent was removed to afford a pale-yellow oil containing small 420 
crystals. The crude product was loaded onto isolute and purified by column chromatography (100% 421 
pet. ether to 20% DCM). The solvent was removed to afford a pale yellow oil (0.500g, 34%). 1H NMR 422 
(400 MHz, Chloroform-d) δ 7.76 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.6 Hz, 2H), 7.34 (s, 2H), 4.75 (t, J = 0.9 423 
Hz, 2H), 0.97 (s, 9H), 0.14 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 191.68, 145.76, 140.96, 135.58, 424 
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134.16, 131.86, 131.10, 129.48, 125.52, 63.60, 26.04, 18.55, -5.17. LC-MS m/z calc. for C20H24Cl3O2Si 425 
[MH]+; 429.1, found; 429.1, tR = 3.78 min. 426 
 427 
 428 
 429 
(4-Chlorophenyl)(2,6-dichloro-4-(hydroxymethyl)phenyl)methanone (39) 430 
To a solution of 38 (0.50 g, 1.2 mmol) in THF (8 mL), TBAF (1M in THF, 2.1 mL, 2.1 mmol) was added. 431 
The mixture was stirred for 5hrs at room temperature. EtOAc was added and the solution washed 432 
twice with sat. NH4Cl(aq) and then water. The organic phase was dried over MgSO4, filtered and the 433 
solvent was removed to afford a white solid. The solid was triturated with pet. ether and collected 434 
by vacuum filtration. (0.282 g, 77%). 1H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 8.6 Hz, 2H), 7.46 435 
(d, J = 8.6 Hz, 2H), 7.39 (s, 2H), 4.76 (d, J = 4.4 Hz, 2H), 2.06 (t, J = 5.8 Hz, 1H). 13C NMR (101 MHz, 436 
CDCl3) δ 191.60, 144.93, 141.09, 136.11, 134.03, 132.12, 131.09, 129.52, 126.18, 63.63. LC-MS m/z 437 
calc. for C14H10Cl3O2 [MH]
+; 315.0, found; 315.1, tR = 2.92 min. 438 
 439 
3,5-dichloro-4-(4’-chlorobenzoyl)benzyl 4’’-methylbenzenesulfonate (40) 440 
To 39 (0.20 g, 0.63 mmol) in chloroform (3 mL) at 0°C, DIPEA (0.22 mL, 1.27 mmol) and tosyl chloride 441 
(0.18 g, 0.95 mmol) were added. The mixture was allowed to warm to room temperature and was 442 
stirred for 24 hrs. 0.5 equivalents (0.06g, 0.32 mmol) of tosyl chloride were added and the mixture 443 
was stirred for a further 24hrs. Sat. NaHCO3 and chloroform were added, and the organic layer was 444 
washed again with sat. NaHCO3 and brine and then dried over MgSO4. Concentration under vacuum 445 
afforded a brown oil which was purified by column chromatography (1:9 EtOAc/pet. ether). The 446 
solvent was removed to afford the title compound as a clear colourless oil which slowly crystallised 447 
to a white solid (0.232g, 78%) 1H NMR (400 MHz, Chloroform-d) δ 7.93 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 448 
8.6 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.43 (s, 2H), 7.41 (d, J = 8.1 Hz, 1H), 4.57 (s, 2H), 2.49 (s, 2H). 13C 449 
NMR (101 MHz, CDCl3) δ 191.11, 146.92, 141.85, 141.23, 141.10, 137.16, 133.81, 132.31, 131.07, 450 
130.36, 129.58, 128.25, 127.20, 44.13, 21.97. 451 
 452 
(4-(Bromomethyl)-2,6-dichlorophenyl)(4’-chlorophenyl)methanone (41) 453 
To a solution of SJM-169-291/293 (0.23 g, 0.74 mmol) in anhydrous THF (2 mL), under a nitrogen 454 
atmosphere, phosphorus tribromide (76.3 µL, 0.81 mmol) was added. The mixture was stirred at 455 
room temperature for 2 hours and then quenched with sat. NaHCO3(aq) and extracted into diethyl 456 
ether twice. The combined organic phases were washed with brine and then dried over MgSO4. The 457 
solvent was removed under vacuum to afford a white solid which was purified by preparative TLC 458 
(5:95 EtOAc/pet. ether) (0.138 g, 49%). 1H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 8.6 Hz, 1H), 459 
7.47 (d, J = 8.6 Hz, 1H), 7.42 (s, 1H), 4.43 (s, 1H). 13C NMR (101 MHz, CDCl3) δ 191.09, 141.44, 141.24, 460 
137.16, 133.81, 132.29, 131.08, 129.58, 128.79, 30.42. LCMS; tR = 3.20min. HRMS (ESI-TOF) m/z calc. 461 
for C14H8 BrCl3O [M+H]
+; 376.8897 found; 376.8892 and 398.8716 [M+Na]+. 462 
 463 
5-Amino-1-(4[4-chlorobenzoyl]-3,5-dichlorobenzyl)-imidazole-4-carboxamide formate (12) 464 
To 5-amino-1H-imidazole-4-carboxamide (0.045g, 0.36 mmol) in DMF (2 mL) at 0°C under a nitrogen 465 
atmosphere, sodium hydride (60% in mineral oil, 14.3 mg, 0.36 mmol) was added. The mixture was 466 
allowed to warm to room temperature and was stirred for 1.25 hours. After this time 41 (0.135 g, 467 
0.36 mmol) in DMF (1 mL) was added dropwise and the reaction mixture was stirred for 3.5 hours. 468 
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The reaction was quenched with water and extracted with ethyl acetate. The organic layer was 469 
washed with water and brine and then dried over MgSO4. The solvent was removed to afford a dark 470 
purple residue which was purified by column chromatography (1:9 MeOH/DCM). As a small impurity 471 
remained the lilac solid was precipitated from EtOAC/pet. ether and then further purified by semi-472 
prep RP-HPLC (40% to 95% B over 15 mins). The title product was afforded as a white solid after 473 
lyophilisation (19.0 mg, 13%). 1H NMR (400 MHz, Methanol-d4) δ 8.46 (s, 1H), 7.77 (d, J = 8.6 Hz, 2H), 474 
7.56 (d, J = 8.7 Hz, 2H), 7.34 (2 x s, 3H), 5.21 (s, 2H). 13C NMR (101 MHz, MeOD) δ 205.02, 178.36, 475 
142.08, 137.85, 137.41, 135.28, 133.22, 132.34, 132.12, 130.62, 128.08, 123.26, 122.31, 46.41. 476 
LCMS m/z calc. for C18H13
35Cl3N4O2 [MH]
+; 423.0, found; 423.1, tR = 2.66 min. HRMS (ESI-TOF) m/z 477 
calc. for C18H14
35Cl3N4O2 [M+H]
+; 423.0177 found; 423.0178 and 444.9996 [M+Na]+. 478 
 479 
3-Amino-1-(4[4-chlorobenzoyl]-3,5-dichlorobenzyl)-pyrazole-4-carboxamide hydroformate 480 
(10) and 5-amino-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-pyrazole-4-carboxamide 481 
formate (11). 482 
To 3-aminopyrazole-4-carboxylic acid amide (0.03 g, 0.24 mmol) in DMF (2 mL) at 0°C, sodium 483 
hydride (9.5 mg, 0.24 mmol) was added. The mixture warmed to room temperature and stirred for 484 
1hr. 41 (0.11 g, 0.24 mmol) in DMF (1 mL) was then added dropwise at 0°C. The mixture was stirred 485 
at room temperature for 1.5hrs then heated at 90°C for 24 hrs. The reaction was quenched with 486 
water and then partitioned between water and DCM. The aqueous phase was extracted with DCM 487 
and the combined organic phases were dried over MgSO4 and the solvent was removed under 488 
vacuum. The resulting yellow solid was purified by column chromatography on silica (5% MeOH in 489 
DCM to 10% MeOH in DCM) to afford the title compound as a white solid (16 mg). NMR showed two 490 
products (N-1 and N-2 isomers) so these were isolated by semi-prep HPLC (35% to 47% B over 16 491 
mins with a 1 min hold at 42% B). The products were isolated as a white solid after lyophilisation; 10 492 
(18.5 mg, 19 %) 11 (16.4 mg, 16 %). 1H NMR (400 MHz, DMSO-d6) 10;  δ 8.53 (s, 1H), 8.05 (s, 1H), 493 
7.77 (d, J = 8.5 Hz, 2H), 7.67 (d, J = 8.5 Hz, 2H), 7.50 (s, 2H), 5.46 (s, 1H), 5.20 (s, 2H). 1H NMR (400 494 
MHz, DMSO-d6) 11; δ 8.53 (s, 1H), 7.80 – 7.71 (m, 3H), 7.67 (d, J = 8.7 Hz, 2H), 7.37 (s, 2H), 6.44 (s, 495 
2H), 5.25 (s, 2H).  13C NMR (101 MHz, MeOD); 10; δ = 192.42, 170.32, 158.79, 142.55, 142.12, 496 
135.31, 133.19, 133.00, 132.11, 130.61, 128.62, 127.43, 102.62, 54.88. 13C NMR (101 MHz, MeOD); 497 
11;  δ = 192.46, 170.32, 151.84, 146.83, 142.48, 142.10, 139.84, 137.57, 135.33, 133.00, 132.11, 498 
130.60, 128.13, 98.26, 63.18. LCMS m/z calc. for C18H13Cl3N4O2 [MH]
+; 423.0, found; 423.1, tR = 3.18 499 
min. HRMS (ESI-TOF) m/z calc. for C18H14Cl3N4O2 [M+H]
+; 423.0177 found; 423.0179 and 444.9996 500 
[M+Na]+. Analytical HPLC; (10) tR = 16.53 mins, purity = 100%, (11) tR = 16.83 mins, purity = 99%. 501 
 502 
3,5-dichloro-4-(4-chlorobenzoyl) benzyl azide (42) 503 
To 41 (50.0 mg, 0.13 mmol) in ethanol (1 mL), sodium azide (17.2 mg, 0.26 mmol) was added. The 504 
mixture was stirred at room temperature for 1 day and then poured into water. The product was 505 
extracted into ether twice and the combined organic phases were washed with water 3 times and 506 
dried over MgSO4. The solvent was removed under a stream of nitrogen and the residue (44.9 mg, 507 
100%) was used directly in the next step without further purification. 508 
 509 
5-amino-1-(3,5-dichloro-4-(4-chlorobenzoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide (CAI) 510 
(9) 511 
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To 2-cyanoacetamide (14.4 mg, 0.17 mmol) in ethanol (1 mL), 30% sodium methoxide in methanol 512 
(31.8 µL, 0.17 mmol) was added. The mixture was heated at reflux for 40 minutes and after cooling 513 
slightly 42 (44.9 mg, 0.13 mmol) in ethanol (1 mL) was added. The mixture was heated at reflux for 514 
1.5 hours and after cooling the solvent was removed under a stream of nitrogen. The crude product 515 
was purified by column chromatography (19:1 DCM/MeOH) to afford the title compound as a yellow 516 
solid (20.4 mg, 36%). 1H NMR (400 MHz, Methanol-d4) δ 7.76 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 8.6 Hz, 517 
2H), 7.37 (s, 2H), 5.49 (s, 2H). 13C NMR (101 MHz, MeOD) δ 192.32, 166.86, 146.75, 142.14, 141.02, 518 
138.00, 135.23, 133.16, 132.10, 130.62, 128.44, 123.23, 54.80. LCMS m/z calc. for C16H13Cl3N5O2 519 
[MH]+; 424.0, found; 424.1, tR = 2.80 min. HRMS (ESI-TOF) m/z calc. for C17H13Cl3N4O2 [M+H]
+; 520 
424.0129 found; 424.0117 and 445.9965 [M+Na]+. 521 
 522 
 523 
 524 
 525 


